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Many medications that are used nowadays have only been studied in adults. For this reason, 
these are not prescribed to children and adolescents, or prescribed off-label, where prescribing 
doctors adjust the dosage of a medication that was approved for adults on the basis of dose 
estimations and pharmacokinetic- and dynamic properties. However, children and adolescents 
cannot be considered as small adults and with the limited information available, it is not known 
whether the drug will be effective and safe. In 2006, the Pediatric Regulation [1] was intro-
duced, leading to children being included in well-controlled pediatric clinical trials, in which the 
efficacy and safety of these medicines can be studied. Even though such clinical trials are nowa-
days conducted, there are still a large number of medications which have not been studied in 
children. For these medications there may be some supportive information available in the lit-
erature or in other information sources such as the Dutch Child Formulary (kinderformularium). 
The doctor will have to make the decision whether or not to prescribe a medication based on 
the available evidence [2]. However, for a number of medications, it is known that these can 
be harmful to the patients of certain age groups. These are considered to be contraindicated 
for use in certain age groups and use of these medications is therefore strongly discouraged. 
Despite this, GPs or specialists may still decide to prescribe these medications if it is deemed 
necessary, and if the benefits outweigh the risks. In this thesis we have discussed many types of 
medication that can be used in children and adolescents, but most studies are focused on the 
psychotropic medications such as methylphenidate and antidepressants.
Methylphenidate
Although many medications are contraindicated for use in children, the opposite may also occur. 
For example, the sympathomimetic psychostimulant methylphenidate was registered for use in 
children but not in adults. Nevertheless, methylphenidate was still largely prescribed despite 
the known contraindication in adults until December 2017 when it was finally registered for use 
in adults. Methylphenidate is one of the most commonly prescribed drugs for the treatment 
of attention deficit/hyperactivity disorder (ADHD), which is a psychiatric disorder affecting ap-
proximately 5% of the children and adolescents worldwide [3]. This drug was contraindicated 
(until recently) for use in patients of 18 years and older because of the cardiovascular risks 
associated with use of these drugs [4, 5]. This was also one of the reasons why this drug was not 
approved for use in adults as previous studies have shown that they may increase heart rate 
and blood pressure, leading to an increased risk of myocardial infarction, stroke and sudden 
cardiac death [5]. Patients may continue treatment with methylphenidate beyond the age of 18 
years if they started using it during their childhood. However, previous studies have also shown 
that the use of methylphenidate in younger patients has decreased, and that methylphenidate 
is currently more often prescribed to patients of 18 years and older than to children [6, 7].
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The prescribing behavior has changed over the past years and this leads to the question on 
which grounds prescribers decide to start treatment with medication such as methylphe-
nidate. There are clear guidelines with regard to ADHD treatment where symptom severity 
and functional impairment may be one of the reasons for medication treatment initiation [8]. 
However, other factors such as age and sex may also be related to treatment initiation with 
methylphenidate. Methylphenidate is known to be more often prescribed to boys than girls, 
which can partly be explained by the fact that ADHD is more often diagnosed in boys than 
girls due to the differences in ADHD symptoms (such as hyperactivity) [9, 10]. Apart from the 
child characteristics, there may also be other factors contributing to treatment initiation with 
medication. The decision to start treatment with medication or even to visit a GP is often made 
by their parents, especially when the children are still young. It usually depends on the parents’ 
knowledge of, and perceptions about ADHD, which may vary across different ethnic and socio-
economic groups [11]. However, the influence of parental factors in treatment initiation with 
methylphenidate in children is understudied. Thus, studies are needed to investigate the differ-
ent factors that may influence the decision to start treatment with methylphenidate, especially 
when other treatment options such as behavioral therapy are also available. Even if treatment 
is started, it also depends on the parents to make sure that these children follow the prescribed 
treatment regimen. Most studies focusing on treatment adherence and persistence are done 
in adults and limited information is available about adherence and persistence in children. For 
this reason, the persistence and adherence in different patient groups (depending on child 
characteristics) warrants further studies. Additionally, the influence of family characteristics 
should also be taken into account.
antidepressants
Other commonly used drugs in children and adolescents are the antidepressants, which were 
first developed in the 1950s. Antidepressants are used to help relieve symptoms of depression 
or anxiety disorders, as well as other conditions. The SSRIs are the most commonly prescribed 
antidepressants as they have fewer adverse effects than other antidepressants [12]. However, 
SSRIs should also be prescribed with caution because of the increased risk of suicide in young 
people for which a black-box warning was released in 2004 [13]. Depression is a mental health 
disorder of which the frequency has increased over the years from childhood to adolescents 
and adulthood [14]. It may have a significant impact when diagnosed during childhood, such 
as impaired school performance and an increased risk of other mental health disorders [14]. 
Thus, early intervention is important to treat these patients. Although a black-box warning was 
released, it is still not clear whether use of antidepressants may lead to an increased risk of 
suicide as the existing literature provides contradictory evidence on this issue [15, 16]. There-
fore, studies are needed to investigate the risks associated with use of these drugs in order to 
support the GPs and other healthcare professionals in the decision making on whether or not 




For the work presented in this thesis, various information sources have been used of which an 
overview is provided in table 1.
The first mentioned source is the Generation R Study, which is a large prospective popu-
lation-based cohort in which children are followed from fetal life onwards. For this study, all 
pregnant women who were resident in Rotterdam and who had a delivery date between April 
2002 and January 2006 were asked to participate in the study. Over the years, detailed and 
extensive data has been collected such as questionnaires, interviews, detailed physical and 
ultrasound examinations, but also behavioral observations of children and their parents [17]. 
These questionnaires also contain questions about the medication that have been used by the 
mothers during pregnancy. In addition, (hard copies of) pharmacy record data were retrieved to 
determine the medications that were dispensed to mothers by pharmacies during pregnancy. 
The medication use by children is partly covered by questionnaires filled out by their parents. 
Furthermore, electronic pharmacy record data were retrieved from pharmacies which include 
all medication that have been dispensed from birth until the age of 15 years in the children. 
Secondly, we have used the database of the Dutch Foundation for Pharmaceutical Statistics 
(Stichting Farmaceutische Kengetallen, SFK), which contains data from more than 97% of all 
community pharmacies in the Netherlands [18]. These data have been collected since 1990 
and include the following information: sex and year of birth, product name, active substance 
according to the Anatomic Therapeutical Chemical code (ATC code) [19], dispensing date, total 
number of drug units per prescription, prescribed daily number of units, dosage regimen, type 
of prescriber (general practitioner, specialist or other) and the first two digits of the postal 
code indicating the region of the pharmacy. Lastly, data for studies in this thesis were retrieved 
from the Integrated Primary Care Information database, which is a longitudinal observational 
dynamic database containing medical records from more than 450 general practitioners (GPs) 
throughout the Netherlands [20]. This database contains medical records such as information 
on demographics, symptoms and diagnosis which is based on the International Classification 
of Primary Care (ICPC) codes and free text, referrals, laboratory findings, discharge letters and 
Table 1. Information sources used in this thesis
source Type setting size Year
2.1/4.1/ 
4.2










3.1 SFK Community pharmacy 
dispensing data
Netherlands ~15.8 million 
people
1990
4.3/ 5.1 IPCI Electronic medical records; 
primary care
Netherlands ~2.5 million 
patients
1989
*SFK indicates Dutch Foundation for Pharmaceutical Statistics; IPCI, integrated primary care information database
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medication prescriptions. These prescriptions contain details on product name, daily dosage, 
the ATC code, and duration of use.
aiMs and ouTline of This Thesis
This thesis aims to present an overview of the use of medication in children and adolescents 
using different information sources, where we evaluated factors related to the prescribing, 
dispensing and taking of medication, and its associated events.
This thesis is divided into seven chapters. The first chapter provides a general introduction 
to the various information sources that are used to study medication use in children and ado-
lescents. Besides, the use of methylphenidate and antidepressants by children and adolescents 
are also briefly discussed, but are covered in more detail in the consecutive chapters.
In chapter 2, we evaluated the concordance between two information sources: self-
reported medication use by pregnant women and pharmacy record data, which can both be 
used for drug utilization studies. In chapter 3, we aimed to determine the medications that are 
contraindicated for use in certain age groups and to what extent these are still dispensed to 
children. In chapter 4, we aimed to determine the different factors associated with treatment 
initiation and continuation with methylphenidate. In chapter 4.1, we studied the maternal 
factors that may be associated with methylphenidate initiation in children as parents play an 
important role in the decision making of treatment in children. Moreover, in chapter 4.2, we 
determined the persistence and adherence to methylphenidate in children of school–going 
age and we studied potential determinants that were associated with adherence. Children 
who started treatment with methylphenidate, may also need to stop at some point, but it 
can also be decided to continue their treatment. Until recently, the use of methylphenidate 
beyond the age of 18 years was contraindicated due to the cardiovascular risks associated with 
methylphenidate use [21]. In chapter 4.3, we aimed to determine the percentage of patients 
who continued treatment beyond the age of 18 years and the different factors associated with 
continued treatment. In chapter 5, we investigated the risk of suicide in current antidepressant 
users compared to past antidepressant users.
Finally, a general discussion and future perspective for upcoming research is presented in 
chapter 6, followed by a summary of all findings in chapter 7.


2 evaluation between self-reports and pharmacy records

2.1 The concordance between self-reported medication use and pharmacy records  
in pregnant women
Cheung K, El Marroun H, Elfrink ME, Jaddoe WVW, 
Visser LE, Stricker BHCh
Pharmacoepidemiol Drug Saf. 2017;26(9)1119-1125.
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AbstrAct
Background and objectives: Several studies have been conducted to assess determinants 
affecting the performance or accuracy of self-reports. These studies are often not focused 
on pregnant women or medical records were used as a data source where it is unclear if 
medications have been dispensed. Therefore, our objective was to evaluate the concordance 
between self-reported medication data and pharmacy records among pregnant women, and 
its determinants.
Methods: We conducted a population-based cohort study within the Generation R study, in 
2,293 pregnant women. The concordance between self-reported medication data and phar-
macy records was calculated for different therapeutic classes using Yule’s Y. We evaluated a 
number of variables as determinant of discordance between both sources through univariate 
and multivariate logistic regression analysis.
Results: The concordance between self-reports and pharmacy records was moderate to good 
for medications used for chronic conditions, such as selective serotonin reuptake inhibitors 
or anti-asthmatic medications (0.88 and 0.79, respectively). Medications that are used occa-
sionally, such as antibiotics, had a lower concordance (0.51). Women with a Turkish or other 
non-western background were more likely to demonstrate discordance between pharmacy 
records and self-reported data, compared to women with a Dutch background (OR Turkish: 
1.63, 95%CI: 1.16-2.29); OR other non-western: 1.33, 95%CI:1.03-1.71).
Conclusions: Further research is needed to assess how the cultural or ethnic differences may 
affect the concordance or discordance between both medication sources. The results of this 
study showed that the use of multiple sources is needed to have a good estimation of the 
medication use during pregnancy.
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inTroduCTion
Maternal medication use has increased over the past years with approximately 80% of women 
receiving at least one prescription medication during pregnancy [22, 23]. Knowledge about 
the medications used during pregnancy is crucial as it may affect the birth outcome. The risk 
of adverse perinatal outcomes or birth defects from medication exposure is often evaluated 
in observational studies, as pregnant women are often not enrolled in clinical trials. These 
studies mostly rely on exposure data collected by a self-reporting tool, as pharmacy records 
are often not available [24-26]. Self-reported data are considered to be an important source of 
information as it may also include over-the-counter medication data, which is not consequently 
registered in the pharmacy. However, patient self-reported data can be subject to errors caused 
by recall bias or social desirability bias, awareness and knowledge [27, 28]. Researchers of a 
previous study found that only 43% of the dispensed prescription medications were reported 
as actually used by pregnant women, but the factors that may have influenced this are not 
clear [29].  Another study showed that pregnant women may be more likely to recall and report 
medication use, because of their increased awareness of potential teratogenic effects of certain 
medications [30]. This may be different for women from ethnic minority groups as the literature 
shows that Hispanic and black women are less likely to seek for information about their health 
on the internet, but also cultural differences and language barriers may play a role [31, 32]. 
Other factors that may influence the accuracy of recalling the prescribed medications include 
age, educational level, alcohol use and general health [28, 33-35].
Currently, there is no ‘golden standard’ to assess maternal medication exposure, as each source 
is prone to bias, which may lead to misclassification of exposure. A number of studies have 
been conducted to assess the determinants that may affect the performance or accuracy of 
self-reports. However, these studies are often not focused on pregnant women in particular or 
the concordance is calculated with medical records and health insurance databases where it 
is not clear if medications have been dispensed [36-39]. Although pharmacy dispensations do 
not reflect patient compliance, a high medication possession ratio in case of chronic use is a 
good proxy indicator of compliance. Moreover, pharmacy records are not affected by patient 
recall. Therefore, pharmacy records can be used as an indicator of the validity of self-reported 
medication data.
In this study, we used self-reported data and pharmacy records collected from a popula-
tion based cohort study in pregnant women to evaluate the concordance of medication use 
between self-reported data and pharmacy records for different therapeutic classes among 
pregnant women, and its determinants.
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MeThods
Study population
This study was conducted within the Generation R study, a population-based prospective 
birth cohort in Rotterdam, the Netherlands [40]. The cohort included 9,778 mothers and their 
children who were born between April 2002 and January 2006. Of these mothers, 8,880 (91%) 
were enrolled in the study during pregnancy and 898 (9%) at birth of their child. Mothers were 
selected based on the availability of pharmacy records in our database. Dispensing records 
were obtained from pharmacies after permission to contact their pharmacy was given, which 
was obtained for the large majority (n=4,930). Furthermore, women with either no pharmacy 
records or self-reported data of the studied therapeutic classes were excluded (n=2,293). The 
flowchart for women included in the current study (n=2,637) is shown in Figure 1. The Genera-
tion R study was approved by the Medical Ethics Committee of the Erasmus Medical Centre, 
Rotterdam. Written informed consent was obtained from all parent-participants.
Pharmacy records
All printed pharmacy records were stored and for each research hypothesis, the relevant 
drugs from each record were entered manually into an automated database. The following 
therapeutic classes were available electronically: Selective Serotonin Reuptake Inhibitors (SS-





















Consented to obtain 
pharmacy records 
(n=5,545) 
Could not find pharmacy 
records (no use) or 
pharmacy records available 
at other pharmacy (n=615)  
Both pharmacy 
records AND self-
reported data available 
(n=2,637)  
Participants in 
Generation R (n=9,778) 
No pharmacy records or 
self-reported data available 
of studied therapeutic 
classes or did not use any 
(n=2,293) 
Enrolled at birth of child 
(n=898) 
Figure 1. Selection of mothers with both pharmacy records and self-report data available. The Generation R 
Study.
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RIs), benzodiazepines, folic acid, antibiotics, anti-asthmatics, antihistamines and non-steroidal 
anti-inflammatory drugs (NSAIDs), as used in earlier studies [41-45]. The medications were 
limited to ‘prescription-only’ medications, but folic acid and antihistamines were also included 
as these medications were relatively more often recorded at pharmacies compared to other 
medications which can also be obtained ‘over-the-counter’ (e.g. NSAIDs).Therefore, we did 
not include NSAIDs in our study. Details of dispensing date, product, number of units, daily 
prescribed number and strength were all available. Use of medication from other therapeutic 
classes was considered as ‘no medication use’ in our study as we focused on these six pre-
scribed therapeutic classes.
Self-reported maternal medication use
Data on maternal medication use was collected using self-reported questionnaires that were 
sent by post to the mothers at each trimester: early pregnancy (gestational age < 18 weeks), 
mid-pregnancy (gestational age 18-25 weeks) and late pregnancy (gestational age >25 weeks). 
In the first trimester, we asked them to fill in the medicines that they had taken in the preceding 
six months. In the second and third trimester we asked which medications they had used in the 
preceding three months [40]. The questionnaires were available in Dutch (also comprehensible 
for Surinamese women), English and Turkish. If needed, women with a Moroccan ethnicity 
were assisted in the filling out of the questionnaires by Moroccan speaking research assistants.
Socioeconomic determinants
Other factors including maternal age at intake, alcohol use, smoking, ethnicity, education level, 
marital status and household income were also obtained using these questionnaires. Ethnicity 
of participating mothers was defined according to the classification of Statistics Netherlands 
[46].  All lifestyle and medication related questions included the question as to whether they 
were exposed to these  factors before and/or during pregnancy to assess the period of expo-
sure.
Statistical analysis
The concordance between self-reported medication data and pharmacy record data was 
calculated for different therapeutic classes using Yule’s Y. This is a measure of agreement for 
dichotomous variables and is less dependent on the prevalence than kappa [47]. It has the 
same possible range of values as kappa (-1 to 1) and are interpreted as follows: <0 no agree-
ment; 0.01-0.20 slight agreement; 0.21-0.40 fair agreement; 0.41-0.60 moderate agreement; 
0.61-0.80 substantial agreement and 0.81-0.99 almost perfect agreement [48]. In addition, we 
calculated the sensitivity and specificity for self-reported medication use compared to pharma-
cy data. We calculated the Odds Ratio (OR), with 95% CI, as the chance of having discordance 
between self-reported data and pharmacy record data (presence pharmacy record/absence 
self-report or absence pharmacy record/ presence self-report). We evaluated the following 
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variables as determinant of discordance (yes/no) between both sources through univariate 
logistic regression analysis: maternal age at intake, alcohol use and smoking during pregnancy, 
ethnicity, maternal education, marital status, net household income and the number of prior 
pregnancies. In addition, a multivariate analysis was performed. On average, 15.6% of data 
across these variables was missing. To avoid the bias of complete case analysis, we accounted 
for missing information on these determinants (data of self-reports and prescription records 
were not imputed) by using multiple imputation methods (n= 10 imputations). Results were 
considered statistically significant at p < 0.05. Finally, in a non-response analysis, we investi-
gated whether any of the determinants was associated with non-response. Statistical analyses 
were performed using IBM SPSS Statistics for Windows, Version 21.0. Armonk, NY: IBM Corp.
resulTs
Characteristics of the study population
A total of 2,637 women used medication during pregnancy according to their pharmacy re-
cords, self-reported data or both (Table 1). Mean maternal age was 29.8 years and the majority 
of the group never smoked during pregnancy (73.4%) or used alcohol while pregnant (48.3%). 
Furthermore, half of the study population was Dutch (50.5%) and only a small proportion of 
these women had a low educational level (5.2%). In addition, only a small percentage of the 
study population did not have a partner (16%) and almost half of these women were married 
(47.9%). The proportion of women with an average income (€900-€2200) was the same as the 
proportion of women with a high income (>€2200, 44.8%) and for the majority of women it was 
their first pregnancy.
Yule’s Y, sensitivity and specificity
Table 2 shows the concordance between self-reported data and pharmacy records for different 
therapeutic classes. Among all classes reported, SSRIs showed the highest rate of concordance 
(0.88), whereas folic acid had the lowest concordance (0.48). Benzodiazepines, anti-asthmatics 
and antihistamines showed a substantial concordance (0.79; 0.68 and 0.61 respectively) and 
for antibiotics, the concordance was considered moderate (0.51). Overall, the specificity levels 
among these therapeutic classes are considered to be high (>90%), with the exception of 
antibiotics (83.9%).  The sensitivity levels on the other hand, showed some greater differences 
among the different therapeutic classes. The sensitivity of SSRIs, benzodiazepines, antibiotics 
and anti-asthmatics ranged from 60.7% to 74.3%, indicating a moderate sensitivity. For the 
other therapeutic classes the sensitivity was somewhat lower (folic acid:36.4% and antihista-
mines:40.6%).
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Table 1 Characteristics of the mothers included in our study
Characteristic Mothers included in the study (n=2,637)
Age in years, mean (SD) 29.8 (5.2)
Alcohol use
 Never during pregnancy 48.3
 Until pregnancy was known 13.9
 Continued during pregnancy 37.8
Smoking
 Never during pregnancy 73.4
 Until pregnancy was known 9.0






 Other western 16.3
 Other non-western 8.0
Maternal education a
 Primary education 5.2
 Secondary education 46.8
 Higher education 48.0
Marital status
 Married 47.9
 Living together 36.1





Number of prior pregnancies
 0 56.0
 1 29.2
 2 or more 14.8
All numbers are given in percentages or mean (SD).  a Highest education followed. Abbreviations: n; number of women, SD; 
standard deviation
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Factors associated with discordance between self-reported data and pharmacy 
records
Table 3 shows the results of the univariate analysis where discordance between both sources 
is associated with an age of 24 years and younger (OR:1.40, 95%CI: 1.05-1.85), a non-Western 
background (OR Turkish:1.91, 95%CI: 1.44-2.54; OR Surinamese:1.52, 95% CI: 1.13-2.04; OR 
Moroccan:1.66, 95%CI: 1.20-2.30 and OR other non-Western:1.49, 95%CI: 1.18-1.88), a lower 
education (OR primary:1.53, 95%CI: 1.05-2.21 and OR secondary:1.43, 95%CI: 1.20-1.70), a 
lower net household income (OR <€900:1.64, 95%CI: 1.19-2.25) and having two or more prior 
pregnancies (OR:1.34, 95%CI: 1.06-1.70). The results of the multivariate analysis only shows 
a significant association with a Turkish background (OR:1.63, 95%CI: 1.16-2.29), another non-
western background (OR: 1.33, 95%CI:1.03-1.71) and having one or more prior pregnancies 
(OR 1 prior pregnancy:1.22, 95%CI: 1.00-1.49 and OR 2 or more prior pregnancies:1.32, 95%CI: 
1.00-1.74).
Table 2 Concordance between self-reported data and pharmacy record data of maternal medication use, by 
therapeutic class (n=2637)
Therapeutic class Yule’s Y a fn rate, % fP rate, % sensitivity b, % specificity b, %
SSRIs 0.88 33.3 0.8 66.7 99.2
Benzodiazepines 0.79 39.3 2.2 60.7 97.8
Folic acid 0.48 63.6 6.4 36.4 93.6
Antibiotics 0.51 34.9 16.1 65.1 83.9
Anti-asthmatics 0.68 25.7 9.5 74.3 90.5
Antihistamines 0.61 59.4 3.7 40.6 96.3
a Calculated using the following formula: Y=( √ad- √bc)/( √ad+√bc), a=pharmacy and self-report; b=only self-report; c=only 
pharmacy record; d=no pharmacy record and self-report. b Sensitivity and specificity of self-reported medication use compared 
to pharmacy records. Abbreviations: FN; false negatives, FP; false positives, n; number of women, SSRI; Selective Serotonin 
Reuptake Inhibitors
Table 3 Determinants that are associated with discordance between self-reported data and pharmacy records 
(n=2,637)
univariate analysis Multivariate analysis
Characteristic N (%) OR 95% CI OR 95% CI
Age 0.98 0.96-1.00
 <25 years 533 (20.2) 1.40 1.05-1.85 -
 25-35 years 1711 (64.9) 1.01 0.79-1.29 -
>35 years 393 (14.9) 1 (ref) -
Alcohol
Never during pregnancy 1279 (48.5) 1 (ref) -
Until pregnancy was known 359 (13.6) 0.80 0.61-1.03 0.99 0.75-1.31
Continued during pregnancy 1001 (37.9) 0.76 0.63-0.91 1.00 0.81-1.23
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disCussion
Pharmacy records are often used as the source of medication exposure information [49-51]. 
However, not all medications are dispensed through pharmacies and therefore, questionnaire 
data are also an important source of information. In this study, we compared the self-reported 
information on prescribed medication use during pregnancy with the presence of medication 
use in pharmacy records for different therapeutic classes of medications. In addition, we 
Table 3 Determinants that are associated with discordance between self-reported data and pharmacy records 
(n=2,637) (continued)
univariate analysis Multivariate analysis
Smoking
Never during pregnancy 1939 (73.5) 1 (ref) -
Until pregnancy was known 234 (8.9) 0.78 0.57-1.07 0.79 0.57-1.10
Continued during pregnancy 465 (17.6) 1.11 0.89-1.38 1.01 0.80-1.29
Ethnicity
Dutch 1332 (50.5) 1 (ref) -
Turkish 249 (9.4) 1.91 1.44-2.54 1.63 1.16-2.29
Surinamese 236 (8.9) 1.52 1.13-2.04 1.30 0.94-1.79
Moroccan 180 (6.8) 1.66 1.20-2.30 1.38 0.94-2.01
Other non-western 429 (16.3) 1.49 1.18-1.88 1.33 1.03-1.71
Other western 212 (8.0) 0.59 0.41-0.86 0.58 0.39-0.84
Maternal education a
Primary education 152 (5.8) 1.53 1.05-2.21 0.96 0.63-1.46
Secondary education 1207 (45.8) 1.43 1.20-1.70 1.10 0.88-1.36
Higher education 1280 (48.5) 1 (ref) -
Marital status
Married 1268 (48.1) 1 (ref) -
Living together 948 (35.9) 0.82 0.68-0.99 0.98 0.79-1.20
No partner 422 (16.0) 1.17 0.92-1.47 1.03 0.77-1.38
Net household income
<€900 414 (15.7) 1.64 1.19-2.25 1.21 0.84-1.73
€900-2200 864 (32.8) 1.16 0.90-1.49 0.93 0.72-1.21
>€2200 1360 (51.6) 1 (ref) -
Number of prior pregnancies
0 1479 (56.1) 1 (ref) -
1 768 (29.1) 1.19 0.99-1.44 1.22 1.00-1.49
2 or more 391 (14.8) 1.34 1.06-1.70 1.32 1.00-1.74
aHighest education followed. Abbreviations: CI; confidence interval, n; number of women , OR; odds ratio, P; p-value
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evaluated the potential factors that are associated with discordance between self-reported 
medication use and pharmacy records.
Overall, we found that medications required for managing chronic conditions (SSRIs and 
anti-asthmatics) had a good or substantial concordance between maternal self-reports and 
pharmacy records. This finding is in line with the results of another study where the authors 
compared self-reports with prescription data in medical records [52]. However, a higher con-
cordance for benzodiazepines was observed in our study compared to the results of a study in 
older adults (0.58), which can be explained by age as studies have shown that older people are 
less likely to recall their medication use [38, 53]. Medications taken for acute conditions (anti-
biotics, folic acid, antihistamines) had a substantial to moderate concordance. Sarangarm et al. 
observed similar results for the concordance of antibiotics, but for folic acid and antihistamines 
we found a lower concordance in the available literature  [37, 52, 53]. This can be explained by 
recall bias, which is less likely to occur in chronic medication than in acute medication use [29, 
54]. Furthermore, the number of drugs that were used during pregnancy may also contribute 
to discordance between both sources. However, we were not able to study this as the num-
ber of women who used more than one drug during their pregnancy was very small (n=97). 
Another possible explanation of the low concordance of folic acid and antihistamines is that 
these medications are available over the counter. Therefore, the use of these medications is 
not always captured in the pharmacy databases and thus contributing to discrepancy between 
both sources.
The sociodemographic and economic characteristics may have influenced the probability of 
concordance. In our study, the number of prior pregnancies was associated with discordance 
between both medication sources, which is not in line with a previous study [37]. The group 
of women with no prior pregnancies was larger (57.1%) compared to those who had 1 to 2 
(28.6%) or more prior pregnancies (14.3%) when it comes to ‘not reporting’ medication use. 
However, the number of women who did not report medication use in the concerning study 
was quite low (n=7) which may explain these differences compared to our study. Furthermore, 
the concordance was lower in women with a Turkish and other non-western background. The 
ethnic differences between self-reported data and data based on medical records from general 
practitioners has been examined in a previous study by Uiters E. et al [39]. They report that 
the level of concordance did not differ between the ethnic groups, implying that the validity of 
self-reported data and medical records did not differ among different ethnic groups. However, 
another study, based on data from a survey and health insurance register, found lower concor-
dance rates on health care utilization (including prescription medication) for immigrants [55]. 
This finding is in line with the current results, where women with a non-western background 
were more likely to have a discordance between self-reported and pharmacy data. Other 
studies showed that adherence to medication may be lower in the ethnic minority groups, 
which means that the prescribed medications are not always taken by these patients [56-58]. 
Non-adherence and lack of persistence should therefore also be taken into consideration. 
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Moreover, the question remains as to how much this discordance between self-reported data 
and pharmacy data is due to cultural or religious factors as they may have different beliefs 
about the use of medication during pregnancy. Finally, a possible explanation is that ethnic 
minorities may face language barriers as Dutch is not their native language and potentially 
did not understand all questions. However, the questionnaires in our study were also avail-
able in Turkish, which means that language barrier should not have hampered these women 
completing the questionnaires. Further research is needed to assess how the cultural or ethnic 
differences may affect the concordance or discordance between both medication sources.
Strengths and Limitations
One of the strengths of this study is that maternal medication use was determined based on 
pharmacy record data, which is more accurate than prescribed medication according to medi-
cal records, because medication can be prescribed but never collected from pharmacies [59]. 
Furthermore, our study population comprises almost 50% of women with a non-Dutch ethnic 
background, thus we were able to study the patterns of concordance among women with dif-
ferent ethnic backgrounds. Despite the strengths of our study, we also had some limitations. 
First, the period of recall was three months, which can be considered as long. Therefore, it is 
likely that women do not recall all medications that have been used in that period. However, we 
believe that pregnant women are more likely to remember what they have used as they may 
be more aware of the risks and safety of medication use during pregnancy [30, 60]. Second, 
the time frames of pharmacy records and self-reported data did not perfectly overlap for all 
participants as there was no possibility to fill out the exact dates of use in the questionnaire. 
Participants who were enrolled in the study during the third trimester of pregnancy may have 
used medications in the first trimester and discontinued medication use during the third 
trimester of pregnancy. Therefore, these women may not have reported use of medications 
during pregnancy. However, given that the specificity is high for all therapeutic classes and the 
proportion of women enrolled at this stage was low (~10%), this scenario is unlikely. Third, the 
majority of our study population was highly educated, which may have affected our results  in 
terms of external validity, showing higher concordance rates compared to the general popula-
tion. However, in our study we were not able to see a significant association between maternal 
education and discordance. Finally, for a large number of women information on medication 
use of both sources was not available, which may increase the likelihood that these women did 
not complete the questionnaire or did not give consent to obtain pharmacy records for certain 
reasons that are related to the demographic and socio economic factors. The results of the non-
response analyses did not show significant differences between both groups for ethnicity, net 
household income, number of prior pregnancies, smoking and alcohol. However, for marital 
status (p-value:0.03) and education (p-value:<0.001) we did see some differences between 
both groups. Despite these differences, we did observe similar results in our study compared to 
the existing literature showing an association between marital status and education as deter-
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minants and discordance between both sources [37, 55, 61, 62]. There is also a possibility that 
the pharmacy records were not available, because the medication was dispensed at another 
pharmacy. Furthermore, some mothers did not receive one or more questionnaires due to a 
variety of logistical reasons and were therefore not able to complete the questionnaires [40]. 
These data are missing completely at random and therefore it does not influence our results.
Conclusion
In conclusion, the results of our study indicate that the concordance between self-reports and 
pharmacy records was moderate to good for medications used for chronic conditions, such as 
antidepressants or anti-asthmatic medications. Medications that are used occasionally, such as 
antibiotics had a lower concordance. The concordance could be explained by the accuracy of 
recall, which may be influenced by factors such as the level of education and prior pregnancies. 
Furthermore, as some of the investigated medications (e.g. folic acid) are also available over 
the counter, the pharmacy records may represent a selection and this may also influence the 
concordance and should be taken into account. Finally, we found that ethnic background may 
play a role in self-reporting the use of medications. Different cultural beliefs about medication 
use during pregnancy, non-adherence and lack of persistence may be an explanation of the 
observed discrepancy among the different ethnic groups. Further research is needed to assess 
how the cultural or ethnic differences may affect the concordance or discordance between 
both medication sources.  The results of this study showed that the use of multiple sources on 
medication use is needed to have a good estimation of the medication use during pregnancy.


3 Contraindicated drugs in children

3.1 Filled prescriptions of age-related contraindicated drugs in children: an 
on-year nationwide cohort study in the 
Netherlands
Cheung K, Teichert M, Moll HA, Stricker BHCh, Visser LE
Int J Clin Pharm. 2018;40(5):1137-1143
38 Chapter 3
Contraindicated drugs in children
AbstrAct
Background and objectives: Children are still prescribed age contraindicated drugs, but infor-
mation about the number and type of these drugs delivered to children in the Netherlands is 
limited.  The objective of this study was to determine the incidence and prevalence of contra-
indicated drugs that were dispensed to children.
Methods: The study was conducted in the Netherlands with routinely collected data from 95% 
of all community pharmacies. We performed a one-year nationwide observational study where 
all patients aged 17 years or younger who have received at least one prescription in 2016 were 
included. Contraindicated drugs were selected, according to the 5th level of ATC code, using 
different information sources. The main outcome measure in this study was the proportion of 
(newly) contraindicated drugs that were dispensed to children.
Results: In total, 3.9% of all children received at least one drug that was contraindicated for age. 
The highest percentage of contraindicated drugs that were dispensed was observed in patients 
aged 1 to 2 years and 13 to 17 years (7.0% and 5.7%, respectively) and the percentage of 
contraindicated drugs that were dispensed was higher in female patients than in male patients 
(4.3% and 3.6%, respectively; p-value <0.001).
Conclusions: The results of this study showed that a substantial percentage of children received 
a contraindicated drug, which is more common in females than in males. Furthermore, the 
information about contraindications is limited and inconsistent.
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inTroduCTion
Many drugs are prescribed off-label as they were not approved for use in children[63],[64]. GPs 
and other prescribers make decisions based on the available evidence, which can be very lim-
ited. Drugs used for treating children are often insufficiently documented with regard to dosing, 
efficacy, and safety in this group. When off-label use is associated with a safety hazard or a risk 
of serious adverse drug reactions, it is described as a contraindication, which means that there 
is sufficient evidence that the drug is or might be harmful and use of these drugs is not advised. 
[65]. In some circumstances there is insufficient information available about the use of drugs 
in children. In this case, it is acceptable to prescribe these drugs if the benefits outweigh the 
risks (warning). Contraindications are always described in the labels of the products concerned 
and should be strictly followed to ensure safe use of these drugs in a specific population[66]. 
One of the recent examples is the label revision for products containing codeine and tramadol 
which states that these drugs are contraindicated for the treatment of pain in children younger 
than age 12. Adverse event reports showed that the use of codeine was associated with re-
spiratory depression and death, with the majority of cases involving children under the age of 
12[67]. This contraindication shows that it is important for healthcare professionals to know 
that prescribing these drugs to children from this particular age group should be avoided and 
alternatives should be used instead. However, in some cases, contraindicated drugs are still 
prescribed when there is a great burden of disease and no alternatives are available[68]. In 
other cases it is also possible that prescribers were not aware of the contraindications in the 
drug labelling[68].
Numerous studies have described the contraindication of medication use in relation to 
specific diseases or patient characteristics, but the focus on age and sex in children in these 
studies is very limited [69-71]. Moreover, these studies are often based on information from 
prescription data and it is not always clear if these drugs were actually dispensed by the phar-
macists. Therefore, we performed a one-year nationwide observational study to determine 
the incidence and prevalence of contraindicated drugs that were dispensed to children with 
routinely collected data from community pharmacies in the Netherlands.
MeThods
Setting
Data were obtained from  the Dutch Foundation for Pharmaceutical Statistics (Stichting Farma-
ceutische Kengetallen). This database contains dispensing data from 95% of all community 
pharmacies in the Netherlands that has been collected since 1990[72]. In the Netherlands, the 
community pharmacies dispense the vast majority of all out-patient prescriptions. For each dis-
pensing, the following information is available: a unique anonymous patient code, sex and year 
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of birth, product name, active substance according to the Anatomic Therapeutical Chemical 
code (ATC code)[19], dispensing date, total number of drug units per prescription, prescribed 
daily number of units, dosage, regimen, type of prescriber (GP, specialist or other healthcare 
professional) and the first two digits of the postal code indicating the region.
Cohort definition
All patients aged 17 years or younger who have received at least one prescription during the 
study period between 1 January 2016 and 31 December 2016 were included. Patients with an 
unknown sex were excluded.
Measures
Drugs that are contraindicated in children were selected according to the 5th level ATC code of 
the World Health Organisation[19]. The prescription codes (PRK code) were used if products 
had to be selected on substance level. The primary reference source that was used to determine 
the contraindication status in children was the Farmacotherapeutisch Kompas 2016 (a national 
formulary provided by the National Health Care Institute) because it contains information of all 
drugs and most details about the topic of interest. The descriptions in the Farmacotherapeutisch 
Kompas are written based on the information in the summary of product characteristcs (SmPC), 
which is considered as a legal document that was approved by the Medicines Evaluation Board 
or the European Medicines Agency. The alternative source of information was the SmPC of the 
products concerned, which was used in case of conflicting information from different sources. 
Furthermore, the Kinderformularium (national formulary for children) was used when the 
information about the contraindication was not clearly described[2]. The following drugs that 
are contraindicated in children below 6 months of age were excluded from the analysis as only 
the year of birth was available: atazanavir, cotrimoxazol, fluticasone, hydrocortison (systemic), 
methylprednisolone, nandrolone, sodium polystyrene sulfonate, pethidine, prilocaine, somat-
ropin, sulfadiazine, tocofersolan and vitamine B complex (parenteral).
Analysis
For all patients, we determined the number of drugs dispensed between 1 January 2016 and 31 
December 2016. In our study, a person was identified as user of a contraindicated drug when 
having at least one contraindicated drug dispensed during the study period. In the analyses, 
we have calculated the cumulative 1-year incidence as the proportion of the total cohort to 
which a contraindicated drug was dispensed in the year 2016 for the first time since birth. In 
addition, the cumulative 1-year prevalence was determined by the proportion of children with 
a contraindicated drug dispensed in the study period, including those who had started before 
1 January 2016. This was also stratified according to age, which was classified into five groups: 
<1 year, 1-2 years, 3-6 years, 7-12 years and 13-17 years. In addition, we investigated the sex 
differences and we calculated the number of contraindicated drugs that were dispensed per 
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region and per type of prescriber. The analyses included almost the entire Dutch population 
and therefore the calculation of confidence intervals for the incidence and prevalence were not 
deemed necessary. We also investigated the information available in the Farmacotherapeutisch 
Kompas, SmPC, Kinderformularium about the reasons for a drug to be contraindicated, which 
are classified into the active ingredient, high/unknown dosage, formulation, lack of information 
about efficacy or safety and the presence of excipients. Finally, we have calculated the number 
of patients, the number of drugs that were dispensed and mean age for the most commonly 
dispensed contraindicated drugs.
resulTs
Patients with an unknown sex (n=122,144) were excluded from the analysis. The remaining 
1,527,021 patients received at least one drug in 2016 where 3.9% of these patients received 
a drug that was contraindicated for age (table 1). The cumulative prevalence was significantly 
higher in females compared to males (4.3% and 3.6%, respectively; p-value <0.001) and highest 
in patients aged 1 to 2 years (7.0%). The majority of patients received only one type of drug 
that was contraindicated for age in the study period (1 drug: 58,597 (6.0%); 2 or more: 1,496 
(0.3%)).




number of children who 





number of dispensed 
contraindicated drugs 
(%)
Overall 1,527,021 60,093 (3.9) 4,454,048 105,106 (2.3)
Sex
 Male 769,903 27,604 (3.6) 2,370,735 48,481 (2.0)
 Female 757,118 32,489 (4.3) 2,083,313 56,625 (2.7)
Age
 <1 year 59,163 2,289 (3.9) 129,022 2,901 (2.2)
 1-2 years 214,506 15,114 (7.0) 277,841 21,295 (7.6)
 3-6 years 336,202 3,093 (0.9) 762,978 5,198 (0.7)
 7-12 years 429,485 11,731 (2.7) 1,253,424 20,456 (1.6)
 13-17 years 487,665 27,866 (5.7) 2,030,783 55,256 (2.7)
Number of
different drugsa
 1 drug 972,451 58,597 (6.0) - -
 2 or more 554,570 1,496 (0.3) - -
aThe number of different drugs was determined based on the ATC7-codes.
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The number of new users of a contraindicated drug in 2016 was 43,206 (2.8%), which was 
significantly higher in females (3.1%) than in males (2.6%) (p-value <0.001). The cumulative inci-
dence was highest in the age categories 1 to 2 years (5.5%) and 13 to 17 years (4.2%), followed 
by the age categories 0 to 1 (2.3%), 7 to 12 years (1.8%) and 3 to 6 years (0.6%). The postal code 
information available for each patient indicated that the number of patients who received a con-
traindicated drug in the Netherlands is fairly equally distributed (North 4.0%; East 3.9%; West 
3.9% and South 4.0%). The majority of patients received the contraindicated drugs from their GP 
(n=1,256,213), followed by medical specialists (n=314,836) and other healthcare professionals 
(n=206,563) but the contraindicated drugs were nevertheless relatively more often prescribed 
by medical specialists than by GPs (GP 3.4%, specialist 4.2% and other 3.6%). The most common 
drugs that were relatively more often prescribed by specialist than GPs or other healthcare 
professionals are hydrocortisone/neomycin/polymyxin B (specialist: 1.26%, GP: 0.48% and other 
healthcare professionals: 0.37%), atropine (specialist: 0.26%; GP:0.003% and other healthcare 
professionals: 0.03%) and dimetindene (specialist: 0.23%; GP:0.06% and other:0.08%).
Overall, the number of patients who received a contraindicated drug was significantly 
higher in females than in males (4.3% and 3.6%, respectively; p-value <0.001) (table 2). Higher 
percentages were observed for female patients in the higher age groups (7-12 years:3.0%, 13-
17 years:6.5%) compared with male patients (7-12 years:2.5%, 13-17 years:4.6%). For male 
patients, higher numbers were observed in the lower age groups (<1 year:4.1%, 1-2 years:7.7%) 
than in female patients (<1 year:3.6%, 1-2 years:6.2%). Cholecalciferol (females: 2.5% and 
males 1.5%) and metoclopramide (females: 0.5% and males: 0.3%) were relatively more often 
prescribed to females than males. Hydrocortisone/neomycine/polymyxine B (males: 0.8% and 
females: 0.5%) and dimetidene (males: 0.13% and females: 0.08%) were relatively more often 
prescribed to male patients.
One of the most common contraindications is due to the active pharmaceutical ingredient, 
which is seen in 49 types of drugs and in 25,875 patients (table 3). Drugs that are contraindi-
cated due to the formulation (e.g. difficulty swallowing) was only observed in one type of drug 
and in 180 patients.
Table 2. Children who were prescribed contraindicated drugs per age group, stratified by sex
Male female
Age Total Contraindicated (%) Total Contraindicated (%)
All ages 769,903 27,604 (3.6) 757,118 32,489 (4.3)
<1 year 33,201 1,357 (4.1) 25,962 932 (3.6)
1-2 years 116,332 9,007 (7.7) 98,174 6,107 (6.2)
3-6 years 177,066 1,668 (0.9) 159,136 1,425 (0.9)
7-12 years 232,991 5,812 (2.5) 196,494 5,919 (3.0)
13-17 years 210,313 9,760 (4.6) 277,352 18,106 (6.5)
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Figure 1 shows that cholecalciferol is one of the most frequently dispensed drugs that is con-
traindicated for age. The combination of hydrocortisone/neomycin/polymyxin b, doxycycline, 
dimetindene, atropine and clobetasol were also in the top ten of the most commonly dispensed 
contraindicated drugs, but these drugs were relatively less dispensed to children with an age 
that is within the contraindication age limit. The other 15 most commonly dispensed drugs 
were: fludrocortisone/neomycine/polymyxin B/lidocaine, lidocaine, promethazine, etoricoxib, 
meloxicam, levodopa/benserazide, temazepam, zolpidem, insulin, zopiclone, rhubarb extract/
salicylic acid, loperamide, scopolamine, norfloxacin (systemic) and sodium phosphate (rectal) 
(results not shown due to low numbers).
Table 4 shows more detailed information from the most commonly dispensed drugs with 
a contraindication for age. For a number of drugs the actual number of contraindicated drugs 
dispensed is lower than the group that was selected based on the ATC codes. Cholecalciferol 
was dispensed to 30,301 children, where 15,988 children (53%) received the oral suspension 
which is contraindicated because of its high dose of vitamin D. Metoclopramide was dispensed 
to 6,253 patients where 110 patients (1.8%) were below the age of 1. The metoclopramide 
suppositories which are contraindicated in children and adolescents less than 18 years, 
were dispensed to 3,559 children (57% of the total number). Doxycycline was dispensed to 
2,670 children with an age lower than 12 years, of whom 305 were less than 8 years (11.4%). 
Furthermore, 268 patients received the drug with the ATC code N04BA02 which not only 
includes levodopa/benserazide, but also levodopa/carbidopa. The contraindicated drug le-
vodopa/benserazide was dispensed to 93 patients (35%). Other commonly dispensed drugs 
that are contraindicated in children below the age of 2 years are dimetindene, levomenthol, 
promethazine, loperamide, fludrocortisone/neomycin/polymyxin B and lidocaine. Temazepam 
and zoplicon are contraindicated for age because the effectiveness and safety of use in children 
have not been studied yet.
Table 3. Different type of reasons for age-related contraindications
reason for contraindication number of different types of drugs 
with a contraindication for age 
(n=63)* n (%)
number of patients receiving a 
contraindicated drug (n=60,093) 
n (%)
Active ingredient 49 (77.8) 25,875 (43.1)
High dosage or unknown dosage 7 (11.1) 32,323 (53.8)
Formulation 1 (1.6) 180 (0.3)
Lack of information about efficacy 
or safety
3 (4.8) 1,675 (2.8)
Presence of excipients 3 (4.8) 40 (0.1)
*Only contraindicated drugs that were dispensed to children by community pharmacies in the Netherlands in 2016 were 
included. Abbreviations: n:number.
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Table 4. Additional information on the most commonly prescribed contraindicated drugs
name of drug 
(aTC code)
Childrena dispensingsb Mean age
(sd)
Potential risk, reason for contraindication
Cholecalciferol 
(A11CC05)c
30,301 60,034 13.3 (4.0) The oral suspension of cholecalciferol and the 
combination with calcium carbonate is contraindicated 
in children aged 17 years and below because it contains 




2,518 6,434 12.7 (3.9)
Metoclopramide 
(A03FA01)
6,253 7,056 12.0 (4.8) Contraindicated in children below the age of 1. 
Metoclopramide suppositories are contraindicated in 





2,670 2,904 10.4 (1.8) Contraindicated in children below the age of 8 
(infections) and 12 years (facial rosacea), because of the 
risk of tooth staining.
Dimetindene 
(R06AB03)
1,560 2,106 0.8 (0.4) Contraindicated in children below the age of 1, because 




904 936 0.9 (0.7) Contraindicated in children below the age of 2, because 
substances containing menthol have been reported to 







800 891 1.4 (0.6) Contraindicated in children below the age of 2 because 
of the possibility of increased absorption of neomycine 
and the kidney function may not be fully developed. 
There is also a potential risk of nephrotoxicity and 
ototoxicity due to neomycin.
Promethazine 
(R06AD02)
643 696 1.9 (0.4) Contraindicated in children below the age of 2, because 
promethazine may lead to severe respiratory depression 
and apnea. A potential association of promethazine use 






268 496 11.4 (4.8) Contraindicated in children and adolescents aged 
24 years and below. Animal studies have suggested 
that benserazide may cause skeletal abnormalities if 
administered before skeletal development is complete.
Temazepam 
(N05CD07)c
226 352 7.0 (3.4) Contraindicated in children aged 11 years and below 
because the safety and effectiveness in children have 
not been established.Zoplicon (N05CF01) 171 283 14.4 (3.9)
Loperamide 
(A07DA03)
112 129 1.3 (0.8) Contraindicated in children below the age of 2 because 
use of loperamide has been associated with fatal 
episodes of paralytic ileus.
aThe number of patients are counted based on the ATC codes. The numbers of patients who have received the medication 
within the age limit for contraindication are shown. Patients outside the age limit were excluded. bThe number of drugs dis-
pensed are counted based on the ATC codes. The number of drugs dispensed are shown of drugs that are contraindicated for 
age. cCholecalciferol and the combination with calcium carbonate have been compiled on one line. Temazepam and Zoplicon 
have been compiled on one line.  Abbreviations: ATC: Anatomical Therapeutic Chemical; SD: Standard Deviation.
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disCussion
It is not always clear why a drug is contraindicated and how many of these drugs are prescribed 
to children despite their contraindication for age. In this nationwide study, we have calculated 
the incidence and prevalence of drugs with a contraindication for the age groups to which 
they were nevertheless dispensed. In our study we observed that 3.9% of all children received 
at least one drug that was contraindicated for age, which are mainly newly prescribed drugs 
(2.8%). These results are almost similar to the results observed in the study by Bensouda-
Grimaldi L. et al. (3.2%)[68]. Our results also showed that male patients received more overall 
prescriptions than female patients, but contraindicated drugs were relatively more often 
dispensed to female patients. The difference in drug use may partly be explained by sex differ-
ences such as the variation in disease prevalence or severity, but the differences in health care 
may also explain this observation[73] [74-76]. Further research is needed to address the sex 
differences in prescribing drugs to children.
Alternatives are available for many  contraindicated drugs, but in some circumstances the 
contraindicated drug is needed. Prescribing an on-label drug does not always have to be accu-
rate, whereas prescribing a contraindicated drug does not have to be considered bad practice 
either. One of the examples is the oral suspension cholecalciferol which is contraindicated 
because of the high dose of vitamin D. These drugs are necessary for children with an impaired 
vitamin D absorption such as cystic fibrosis or serious vitamin D deficiency in rachitis. However, 
it is not clear if they were all prescribed for these type of indications, as we observed a large 
number of patients who received the high dose of Vitamin D in our study. The increase of 
vitamin D use since the global recognition of vitamin D deficiency in the general population 
has also led to an increase in vitamin D intoxications, which were partly due to inappropriate 
prescribing[77]. This may also be explained by the differences between information sources 
that was observed as the oral suspension with a high dose of vitamin D was only mentioned 
in the Farmacotherapeutisch Kompas, but not mentioned or described in the Kinderformulary. 
Specialists, GPs or other healthcare professionals may use different information sources as we 
also observed that not only specialist were more likely to prescribe contraindicated drugs, but 
also the type of drugs between specialists and GPs together with other healthcare profession-
als were slightly different.
Metoclopramide is still prescribed for chronic use for the indication symptomatic gastro-
esophageal reflux as the substantial need is not met by other medications[78]. However, the 
contraindication of metoclopramide suppositories in higher age groups is not very clear as it 
is described as a contraindication, but was also described as a warning according to the same 
information source[20]. Another commonly prescribed drug that is contraindicated in children 
is doxycycline, which should be avoided because of its known adverse effect; tooth staining[79]. 
It is possible that doxycycline is still prescribed despite the label warning as it is considered as 
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one of the most effective treatments for tick borne diseases or because recent studies showed 
no visible dental staining in children [80],[81],[82].
Strengths and limitations
One of the strengths of our study is that we used a population-based dispensing database 
which registers drugs that were dispensed in more than 95% of all community pharmacies 
in the Netherlands. Pharmacists play an essential role in drug safety and it is likely that the 
number of contraindicated drugs is higher in prescription data than in our study as we have 
used dispensing data. Detailed information was available of all drugs that were dispensed to 
children. The relatively long history available also enabled us to study any drugs that were 
dispensed since birth to determine the 1-year cumulative incidence and prevalence. Our study 
also has several limitations. Our data does not include the drugs that were dispensed by hos-
pital pharmacies where the numbers of contraindicated drugs that were dispensed may be 
higher. No information about the month of birth was not available. Therefore, we only included 
drugs in our analysis where the contraindication for age was based on the number of years 
and not months. Also, no information was available with regard to the indication of the drugs 
prescribed.
Conclusion
The results of this study showed that a substantial percentage of children received a dispensed 
drug which is contraindicated for that age, which is more common in females than in males. Sex 
differences in disease prevalence or healthcare may explain this observation. We also observed 
that the information about the contraindication (contraindication or warning and the reason) 
is limited and not consistent between the different information sources. Since prescribing 
an on-label drug can be inaccurate, as much as prescribing an contraindication drug can be 
good practice, it is important that all prescribers and healthcare professionals are informed 
sufficiently about the contraindications.  Further research is needed to investigate the sex dif-
ferences and the reasons for prescribing particular drugs despite their contraindication for age.
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AbstrAct
Background and objectives: Methylphenidate is widely used to treat children with attention 
deficit hyperactivity disorder (ADHD). Apart from the indication, multiple factors may contrib-
ute to the decision to initiate treatment such as maternal sociodemographic factors of which 
relatively little is known. Therefore, the objective was to investigate the association between 
these factors and child methylphenidate initiation.
Methods: The study population included 4,243 children with pharmacy dispensing records from 
the Generation R Study in the Netherlands. Maternal sociodemographic characteristics were 
tested as determinants of methylphenidate initiation through a time-dependent Cox regression 
analysis with date of first prescription as event date. Subsequently, we stratified by mother-
reported clinically relevant ADHD symptoms.
Results: Methylphenidate was less likely to be prescribed to girls (adjusted hazard ratio 
(HR):0.34,95%CI:0.24-0.49) and to children born to a mother with a non-western ethnicity (ad-
justed HR:0.41,95%CI:0.28-0.60) compared to mothers of Dutch-Caucasian ethnicity, and more 
likely if mothers completed secondary education compared to a higher education (adjusted 
HR:1.52,95%CI:1.09-2.12). After stratification on ADHD symptoms, the associations remained 
similar, except for maternal education where no association was found in children with ADHD 
symptoms. Children without ADHD symptoms were more likely to receive methylphenidate 
when their mother completed a low (adjusted HR:2.29,95%CI:1.10-4.77) or secondary (ad-
justed HR:1.71,95%CI:1.16-2.54) education.
Conclusion:  The current study showed that even when there are no reported ADHD symptoms, 
boys and children born to a mother of Dutch-Caucasian ethnicity or a low maternal educa-
tion were  more likely to receive methylphenidate treatment. Treatment initiation in children 
without ADHD symptoms should be further investigated.
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inTroduCTion
Worldwide, 5% of children will develop or have symptoms of attention deficit hyperactivity 
disorder (ADHD) [83]. Stimulant medication is widely used for the treatment of ADHD of which 
methylphenidate is considered the first choice of pharmacological treatment [84]. However, 
not all children eligible for methylphenidate treatment receive the medication and conversely 
some children may receive methylphenidate when it is not needed [85].  Even though, there are 
clear guidelines with regard to ADHD treatment, symptom severity and functional impairment 
are not the sole determinants of treatment initiation. Numerous studies have explored other 
factors that might contribute to the use of stimulant medication in children diagnosed with 
ADHD [86, 87]. One of the factors known to be related to initiation with stimulant medica-
tion is the patient’s sex. Stimulants are more often prescribed to boys than girls, which can 
partly be explained by the fact that ADHD is more often diagnosed in boys than in girls and 
this may reflect differences in ADHD symptoms between boys and girls [88-90]. Apart from 
child characteristics, the prescribing behavior of physicians as well as the availability of non-
pharmacological treatment options to the family are important [91-93].
Not every child diagnosed with ADHD receives pharmacological treatment[94]. While 
symptom’s severity as well as non-response to non-pharmacological interventions play an 
important role in the initiation of pharmacological treatment [94], there may be other factors 
contributing to a family’s decision to visit a general practitioner or specialist, a child psychiatrist 
or to start medication [95]. Children often rely on caregivers for support and management 
of chronic conditions involving taking medications, where mothers are mostly considered 
as the primary caregiver [96]. However, the importance of the mothers, notably maternal 
characteristics in determining methylphenidate treatment initiation should be studied further 
[97-99]. Previous studies showed that the utilization of ADHD medication may be influenced 
by sociodemographic factors such as ethnicity and socioeconomic status [89, 100].  However, 
these studies do not address the presence or absence of any ADHD related symptoms in these 
children, which may also vary across the different sociodemographic groups [11, 101].
The objective of our study was to investigate the association between maternal sociodemo-
graphic and prenatal lifestyle factors in relation to child methylphenidate treatment initiation. 
Subsequently, we performed analyses stratified by the presence of maternal reports of clinically 
relevant ADHD symptoms in children using the determinants that were significantly associated 
with child methylphenidate prescription.
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MeThods
Design & study population
The study was conducted within The Generation R Study, which is a large prospective popula-
tion-based cohort study investigating children’s health from fetal life onwards in Rotterdam, the 
Netherlands [17]. Pregnant women who were resident in Rotterdam and who had a delivery 
date between April 2002 and January 2006 were asked to participate in the study. In this co-
hort, detailed and extensive data collection has been conducted, which include questionnaires, 
interviews, and behavioral observations of children and their parents [17]. In addition, we 
retrieved pharmacy records from community pharmacies throughout Rotterdam, depending 
on where the child resided and collected their prescription-only drugs. In total, 9,778 mothers 
were enrolled in the study and gave birth to 9,749 live born children (Figure 1). Of this group, 
7,896 children and their parents were invited to participate in the follow-up study (56 died; 
1,086 withdrawn from study; 639 lost to follow-up). Children were excluded from the study 
if their parents chose to later withdraw from the study (n=74). They were also excluded if 
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Figure 1. Selection of the study population
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no consent by their parents was provided (n=1,084) or because no consent was given by the 
pharmacist or the child could not be found in the pharmacy  (n=2,567). Pharmacy records could 
be obtained from 4,243 children. The Medical Ethics Committee of the Erasmus Medical Center 
approved all study procedures, and parents provided written informed consent.
Child Methylphenidate prescription
Pharmacy records of Generation R participants were collected based on the living area of 
their mothers (northern, southern, western of eastern part of Rotterdam). This information 
was used to determine at which pharmacies they may collect their medication. Pharmacists 
were contacted and asked for consent to retrieve the pharmacy records. Children may collect 
their medication at more than one pharmacy and these pharmacy records were all linked to 
one particular child. Pharmacy records of children may not be available because either their 
pharmacy or their parents did not give consent to retrieve these records or because the child’s 
pharmacy could not be found.
For 4,243 individuals in The Generation R Study, all prescriptions which were filled at their 
pharmacy during the entire study period were gathered starting at birth. For each prescrip-
tion we had the product name, anatomical therapeutic chemical (ATC) code [102] , date of 
filling, number of delivered tablets/capsules, and prescribed daily number of doses. All study 
participants were followed from date of birth until a first prescription of methylphenidate or 
end of the study period at 1 September 2017, whichever came first. Information about the use 
of ADHD medication (N06BA) was obtained from the collected pharmacy dispensing records. 
Furthermore, information about the type of prescriber of the first methylphenidate prescrip-
tion (e.g. general practitioner, specialist or at the hospital) was available, which was retrieved 
from the electronic pharmacy records as well.
Child ADHD symptoms
The Child Behavior Checklist (CBCL/1.5-5 and CBCL/6-18) was used to obtain information about 
behavioral and emotional problems in children [103]. The CBCL is a questionnaire that was 
filled out by mothers when children were 1.5, 3, 5 and 9 years of age. The CBCL/6-18 was 
only used at the 9 years assessment. The CBCL contains items on the child’s behavioral and 
emotional problems during the preceding 2 months which were scored on a 3-point scale; 6 of 
the items make up de attention-deficit/hyperactivity problems scale. Children were classified 
as having ADHD symptoms in the borderline clinical range, when the cut-off score was above 
the 93rd percentile. It has been reported that these DSM-oriented scales provide accurate and 
supplementary information on clinical diagnosis with a good reliability and validity for the CBCL 
[103, 104]. For the statistical analysis, we used the last questionnaire that was filled out by 
the mother prior to date of first methylphenidate prescription. The average time between the 
completion of the last CBCL and first prescription of methylphenidate was 2.9 years (SD: 3.6).
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Child and maternal characteristics
The following maternal lifestyle and demographic characteristics were considered as potential 
determinants for starting treatment with methylphenidate: maternal age at intake, ethnic-
ity (Dutch-Caucasian or other Western, non-western, defined according to the classification 
of Statistics Netherlands [105]), household income (<€1200, >€1200 and <2000, >€2000 per 
month), educational level (primary, secondary, higher), marital status (married, living together, 
no partner), alcohol use (yes/no), caffeine intake (yes/no) and smoking during pregnancy (yes/
no) [106]. Maternal psychopathology in mid-pregnancy was assessed, using the Brief Symptom 
Inventory (BSI) which is a validated self-report questionnaire which includes a spectrum of 
psychiatric symptoms. A weighted sum score above 0.75 means that clinically relevant psy-
chopathology symptoms were present [107, 108]. In addition,  the use of selective serotonin 
reuptake inhibitors (SSRIs) during pregnancy (the most frequently used antidepressant in our 
study), which was obtained from pharmacy records and self-reported information [109]. This 
information from mothers was collected during pregnancy or at birth of their child. Finally, we 
also considered child’s sex as a potential determinant.
Analysis
Child and family characteristics were presented for all children with pharmacy records, which 
also included the type of prescriber, age of first methylphenidate prescription and the life style 
factors of the mothers. Second, we investigated which maternal lifestyle and demographic 
characteristics were related to methylphenidate initiation. For the main analyses, we calcu-
lated the hazard ratio (HR), with 95% confidence interval (CI) for each determinant associated 
with initiation of methylphenidate using a time-dependent Cox regression model, where non-
methylphenidate users can serve as a control more than one time [110]. A time-dependent 
model was used, because the CBCL questionnaires were completed at different points in time 
(1.5, 3, 5 and 9 years). For this analysis, we considered the presence of clinically relevant 
ADHD symptoms based on the CBCL questionnaire data completed prior to the date of first 
methylphenidate prescription. As determinants of methylphenidate treatment initiation, we 
considered all above-mentioned maternal and child characteristics in the univariate analysis. 
Second, a multivariable Cox regression analysis was performed with the variables that were 
univariably associated. Separately, we tested the interaction between maternal education and 
ethnicity in the post-hoc analysis with an interaction term. Finally, we performed analyses 
stratified by clinically relevant ADHD symptoms (above 93rd percentile) using the factors that 
were associated with child methylphenidate prescription in the main analysis.
First, we performed complete-case analyses. In the non-response analysis, we explored 
differences between mothers and children of responders and non-responders. In the sensitivity 
analysis, we performed the same analysis using multiple imputation of the covariates (where 
less than 30% was missing) using the expectation maximization algorithm to deal with miss-
Chapter 4.1 57
Maternal sociodemographic factors are associated with methylphenidate initiation in children in the Netherlands
ing data. Results were considered statistically significant at p<0.05. Statistical analyses were 
performed using IBM SPSS Statistics for Windows, version 21.0 (IBM Corp., Armonk, NY).
resulTs
Child methylphenidate prescription
Pharmacy records were available for 4,243 children. A total of 295 children were prescribed 
an ADHD medication, where 291 (99%) received methylphenidate. Due to the small number 
of other ADHD medication (dexamphetamine n=3 and atomoxetine n=1 ) prescribed, we 
only analyzed data of children who started their treatment with methylphenidate. In total, 
291 children received a methylphenidate prescription. The average age of receiving their first 
methylphenidate prescription was 9.4 years. Of the children who received methylphenidate, 
207 children received their first methylphenidate prescription from a specialist (71%) and they 
were more often boys (n=221, 75.9%).
Demographic and lifestyle characteristics
In Table 1, the characteristics of the study population are shown. Half of the children who were 
included in our study were girls (n=2,066, 48.7%). Of those children whose mother filled in 
the CBCL questionnaires (n=2,070), 179 (8.6%) had ADHD symptoms above the cut off score. 
Furthermore, 1.621 (38.2%) mothers had a non-western background, 2,016 (47.5%) had a 
relatively high monthly household income (€>2000) and only a small percentage had a low 
educational level (n=361, 8.5%).
Table 1. Maternal and child characteristics of study population
Characteristic  n (%), n=4,243
Sex, girl 2,066 (48.7)
ADHD symptoms present (CBCL by mother)a
   No 1,891 (44.6)
   Yes 179 (4.2)
Age of first methylphenidate prescription, mean (SD)* 9.4 (2.2)
Type prescriber *
   No methylphenidate prescription 3,955 (93.2)
   Specialist 209 (4.9)
   General Practitioner 37 (0.9)
   Hospital 10 (0.2)
Maternal age (at intake) in years, mean (SD) 30.6 (5.2)
Parity
   1 2,260 (53.3)
   >1 1,983 (46.7)
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Table 1. Maternal and child characteristics of study population (continued)
Characteristic  n (%), n=4,243
Ethnicity mother
   Dutch-Caucasian and other western 2,480 (58.4)
   Non-western 1,621 (38.2)
Household income
   <€1200 570 (13.4)
   €1200-2000 571 (13.5)
   €>2000 2,016 (47.5)
Maternal education level
   No education/ primary education 361 (8.5)
   Secondary education 1,708 (40.3)
   Higher education 1,747 (41.2)
Marital status
   Married 1,921 (45.3)
   Living together 1,418 (33.4)
   No partner 484 (11.4)
Smoking during pregnancy
   No 3,056 (72.0)
   Yes 596 (14.0)
Alcohol use during pregnancy
   No 1,991 (46.9)
   Yes 1,322 (31.2)
Caffeine intake during pregnancy
   No 2,105 (49.6)
   Yes 1,468 (34.6)
Maternal psychopathology (BSI)
   <0.76 2,770 (65.3)
   0.76 and higher 485 (11.4)
SSRI use during pregnancy
   No 1,798 (42.4)
   Yes 36 (0.8)
Numbers are given in numbers (percentages) unless stated otherwise. The numbers of the missing values are not shown 
in this table, but are as follows: type prescriber 22 (0.5%); reported ADHD symptoms 2,173 (51.2%); ethnicity 142 (3.3%); 
household income 1,086 (25.6%); maternal education 427 (10.1%); marital status 420 (9.9%); smoking during pregnancy 591 
(14%); alcohol use during pregnancy 930 (21.9%); caffeine intake during pregnancy 670 (15.8%); maternal psychopathology 
988 (23.3%) and SSRI use during pregnancy 2,409 (56.8%). *The information about the type of prescriber was only provided 
of children who received methylphenidate (n=291). a Clinically relevant ADHD symptoms: Children were classified as having 
ADHD symptoms in the borderline clinical range when their cut-off score was above the 93rd percentile. BSI indicates Brief 
Symptom Inventory; N, number of children; SD, standard deviation; SSRI, selective serotonin reuptake inhibitors. All numbers 
are given in percentages or mean (SD).
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Determinants of methylphenidate treatment initiation
In the multivariable analysis (Table 2), we found that girls were less likely to be treated with 
methylphenidate than boys (adjusted HR: 0.34, 95%CI: 0.24-0.49). As expected, children were 
more likely to receive a methylphenidate prescription when mothers reported clinically rel-
evant child ADHD symptoms (adjusted HR: 8.67, 95%CI: 6.25-12.02). We observed that children 
were more likely to start treatment with methylphenidate when mothers completed secondary 
school (adjusted HR: 1.52, 95%CI: 1.09-2.12) compared to mothers with a higher educational 
level. Furthermore, a non-western ethnicity of mothers was associated with a lower likelihood 
of methylphenidate treatment (adjusted HR: 0.41, 95%CI: 0.28-0.60) compared to a Dutch-
Caucasian or other western background. Finally, the interaction between maternal education 
and maternal ethnicity was found to be significant (P: 0.001). Children whose mother received 
a secondary education as compared to a higher education in the western group were more 
likely to receive methylphenidate (HR:1.93, 95%CI: 1.45-2.58). In the non-western group, no 
significant association was found (no/ primary education HR: 0.70, 95%CI: 0.36-1.38; secondary 
education HR: 0.71, 95%CI: 0.42-1.20).
Table 2.  Maternal and child factors associated with methylphenidate treatment initiation
Characteristic Cases, n (%)
(n=291)
Crude hr, 95%Ci adjusted hr, 95%Ci
(cases, n=180)
Sex child
    Boy 221 (75.9) Ref Ref
    Girl 70 (24.1) 0.31 (0.24-0.41) 0.34 (0.24-0.49)
ADHD symptoms present (CBCL by 
mother)a
   No 128 (44.0) Ref Ref
   Yes 78 (26.8) 9.06 (6.71-12.23) 8.67 (6.25-12.02)
Maternal age at baseline, years
   <25 44 (15.1) Ref
   25-30 85 (29.2) 0.87 (0.59-1.27)
   31-36 123 (42.3) 0.77 (0.54-1.10)
   >36 39 (13.4) 0.81 (0.52-1.27)
Parity
   1 154 (52.9) Ref
   >1 137 (47.1) 1.02 (0.80-1.29)
Ethnicity mother
   Dutch-Caucasian and other 
western
201 (69.1) Ref Ref
   Non-western 82 (28.2) 0.60 (0.46-0.79) 0.41 (0.28-0.60)
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Stratification by ADHD symptoms
Absence of ADHD symptoms
Table 3 shows that girls without clinically relevant ADHD symptoms were less likely to receive 
a methylphenidate prescription than boys (adjusted HR: 0.25, 95%CI: 0.16-0.39). Children with 
Table 2.  Maternal and child factors associated with methylphenidate treatment initiation (continued)
Characteristic Cases, n (%)
(n=291)
Crude hr, 95%Ci adjusted hr, 95%Ci
(cases, n=180)
Household income
   <€1200 29 (10.0) 0.67 (0.44-1.00)
   €1200-2000 38 (13.1) 0.89 (0.61-1.28)
   €>2000 150 (51.5) Ref
Maternal educational level
   No education/ primary 20 (6.9) 0.91 (0.56-1.49) 1.04 (0.52-2.06)
   Secondary 138 (47.4) 1.37 (1.06-1.78) 1.52 (1.09-2.12)
   Higher 106 (36.4) Ref ref
Marital status
   Married 113 (38.8) Ref
   Living together 106 (36.4) 1.29 (0.98-1.70)
   No partner 40 (13.7) 1.44 (0.99-2.10)
Alcohol use during pregnancy
   No 124 (42.6) Ref
   Yes 100 (34.4) 1.23 (0.94-1.62)
Smoking during pregnancy
   No 196 (67.4) Ref Ref
   Yes 55 (18.9) 1.48 (1.09-2.03) 1.02 (0.70-1.48)
Caffeine intake during pregnancy
   No 143 (49.1) Ref
   Yes 97 (33.3) 1.04 (0.80-1.35)
Maternal psychopathology (BSI)
   <0.76 178 (61.2) Ref
   0.76 and higher 33 (11.3) 1.06 (0.72-1.56)
SSRI use during pregnancy
   No 132 (45.4) Ref
   Yes 4 (1.4) 1.58 (0.55-4.53)
A time-dependent model was used where the ADHD scores of the last completed CBCL questionnaire prior to methylphenidate 
prescription was considered. In the adjusted model we included all univariably associated determinants. The number of non-
methylphenidate users are not presented in the table due to the time component of the model where non-methylphenidate 
users can serve as a control more than once. a Clinically relevant ADHD symptoms: Children were classified as having ADHD 
symptoms in the borderline clinical range when their cut-off score was above the 93rd percentile ADHD indicates attention 
deficit hyperactivity disorders, BSI, Brief Symptom Inventory; CBCL, Child Behavior Checklist CI, confidence interval; HR, hazard 
ratio; N, number of children; SD, standard deviation; SSRI, selective serotonin reuptake inhibitor.
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mothers of a non-western background were less likely to receive a methylphenidate prescrip-
tion than those with a Dutch-Caucasian background (adjusted HR: 0.42, 95%CI: 0.26-0.68). 
Furthermore, we found that children were more likely to receive a methylphenidate prescrip-
tion when mothers completed lower education than those who completed high education (no 
education/ primary education adjusted HR: 2.29, 95%CI: 1.10-4.77 and secondary education 
adjusted HR: 1.71, 95%CI: 1.16-2.54).
Table 3: Maternal and child factors associated with methylphenidate treatment initiation stratified by the 
presence and absence of clinically relevant ADHD symptoms
CbCl filled out by 
the mother












   Boy 101 Ref Ref
   Girl 27 0.26 (0.17-0.39) 0.25 (0.16-0.39)
Ethnicity
   Dutch
   Caucasian and
   other western
94 Ref Ref
   Non-western 32 0.51 (0.33-0.77) 0.42 (0.26-0.68)
Maternal education
   No education/
   primary
11 1.20 (0.61-2.35) 2.29 (1.10-4.77)
   Secondary 57 1.33 (0.90-1.95) 1.71 (1.16-2.54)













   Boy 58 Ref Ref
   Girl 20 0.54 (0.32-0.89) 0.53 (0.32-0.90)
Ethnicity
   Dutch
   Caucasian and
   other western
55 Ref Ref
   Non-western 23 0.41 (0.25-0.68) 0.45 (0.26-0.77)
Maternal education
   No education/
   primary
5 0.38 (0.14-1.03) 0.60 (0.21-1.70)
   Secondary 44 0.92 (0.55-1.54) 1.10 (0.65-1.86)
   Higher 26 Ref Ref
A time-dependent model was used where the ADHD scores of the last completed CBCL questionnaire prior to methylpheni-
date prescription was considered. In the adjusted model we included all determinants. The number of non-methylphenidate 
users are not presented in the table due to the time component of the model where non-methylphenidate users can serve 
as a control more than one time a Clinically relevant ADHD symptoms: Children were classified as having ADHD symptoms in 
the borderline clinical range when their cut-off score was above the 93rd percentile. bCorrected for time between completion 
of CBCL and first methylphenidate prescription. ADHD indicates attention-deficit hyperactivity disorder; CBCL, child behavior 
checklist; CI, confidence interval; HR, hazard ratio; N, number of children.
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Presence of ADHD symptoms
When child ADHD symptoms above the cut-off were reported, we found that girls were less 
likely to receive a methylphenidate prescription than boys (adjusted HR: 0.53, 95%CI: 0.32-
0.90) (Table 3). Children of non-western mothers were less likely to receive a methylphenidate 
prescription compared to those of mothers with a Dutch-Caucasian or other western back-
ground (adjusted HR: 0.45, 95%CI: 0.26-0.77).
Sensitivity analyses
In the multivariable analysis with imputed data we found similar results: direction and size of 
the effect estimates overall did not change much. We found that girls were less likely to receive 
methylphenidate (adjusted HR: 0.31, 95%CI: 0.21-0.47) or when they had a mother with a non-
western background (adjusted HR: 0.48, 95%CI: 0.31-0.75). Children were more likely to receive 
a methylphenidate prescription when they had ADHD symptoms above the cut-off reported 
by their mothers (adjusted HR: 10.12, 95%CI: 6.95-14.74). However, the  association between 
methylphenidate initiation and a low maternal education was non-significant (no/primary 
education adjusted HR: 2.01, 95%CI: 0.94-4.28; secondary education adjusted HR: 1.37, 95%CI: 
0.94-2.01).
Non-response analyses
For the variables that were included in the analyses, less than 30% were missing, except for SSRI 
use during pregnancy (56.8%) and the reported clinically relevant ADHD symptoms (51.2%). 
The non-response analysis showed no significant differences between children with and with-
out information for the maternal characteristics. However, we found that 2,173 women did not 
complete the CBCL questionnaires at all or did not complete the questionnaire prior to the first 
prescription of methylphenidate. A dropout analysis on this variable showed that the missing 
of the CBCL questionnaire was not significantly associated with sex, but it was associated with 
ethnicity (P<0.001), maternal education (P<0.001) and methylphenidate initiation (P<0.001).
The analysis in the group without information on ADHD symptoms (missing information) 
showed similar results for sex and ethnicity (girls adjusted HR 0.49, 95%CI: 0.30-0.83 and non-
western background (adjusted HR  0.61, 95%CI 0.36-1.03). For maternal education, we found 
that a lower education was significantly associated with a decreased risk of methylphenidate 
use compared to higher education (no education/ primary HR 0.31, 95%CI 0.11-0.91).
Pharmacy records were not available for half of the cohort participants (results not shown in 
table). For children of whom no pharmacy records were available, we found that their mothers 
were significantly younger (maternal age 29.6 vs 30.6, P<0.001), had a lower household income 
(20.6% <1200 vs 18.1%, P<0.02), were lower educated (12.0% no education/primary education 
vs 9.5%, P<0.001), more often did not have a partner (15.6% no partner vs 12.7%, P0.001), 
used less alcohol during pregnancy (35.4% vs 39.9%, P<0.001), smoked more during pregnancy 
(19.7% vs 16.3%, P<0.001) and used less caffeine during pregnancy (61.9% vs 58.9%).
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disCussion
Main findings
In the current study, we found that several child and maternal sociodemographic factors were 
related to methylphenidate treatment initiation. In our study we were able to study these 
determinants stratified by the presence and absence of clinically relevant ADHD symptoms. 
Our findings show that methylphenidate was more frequently prescribed to boys than girls. It 
also shows that children of mothers with a non-western background were less likely to receive 
methylphenidate treatment than those of mothers with a Dutch-Caucasian or other western 
background. These findings are both in line with results that have been shown in previous 
studies [89, 90, 111].  However, the previous studies as described above only addressed the 
association with sociodemographic factors in patients with an ADHD diagnosis. In our study, 
we found that even when no ADHD symptoms were reported by mothers, boys and children 
born to mothers with a western ethnic background were still more likely to receive methylphe-
nidate.  Furthermore, we found that a low and secondary maternal education was associated 
with methylphenidate prescription in children without reported symptoms. A previous study 
of Russel et al., found no significant association between maternal education and medication 
use in children in a UK population [88]. This could also be explained by the differences in the 
educational system of the Netherlands and the UK. It is also possible that they did not find 
the association as they only explored the sociodemographic factors of medication use among 
children with ADHD.
Explanations for these findings
First, sex differences with regard to use of methylphenidate or other stimulants is probably 
related to the diagnosis of ADHD, which is more common in boys than girls [9]. Moreover, 
boys with clinically ADHD, present more outwardly signs of ADHD, such as hyperactive and 
impulsive behavior, while girls present more inwardly signs, such as inattentiveness and low 
self-esteem  [112]. In addition, girls may express their difficulties differently; for example emo-
tional problems are more common in girls with ADHD than in boys. Also, boys tend to show 
more hyperactivity, than girls [10, 113]. This may both lead to boys being diagnosed with ADHD 
more often as well as earlier initiation of pharmacological treatment as shown previously [88]. 
However, in our study we observed that girls are still less likely to be treated with methylphe-
nidate irrespective of the presence of ADHD symptoms. It is possible that girls may be less 
qualified as their symptoms are not considered severe enough [114]. However, it could also 
imply that girls with ADHD symptoms are undertreated while on the other hand boys without 
ADHD may be overtreated [115]. Parents may find it more difficult to cope with the hyperactive 
and impulsive behavior which is more prevalent in boys and this could also be the reason why 
boys are more likely to be treated with medication.
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Second, we showed that children without clinically relevant ADHD symptoms with mothers 
who only had limited education (no education, primary and secondary education) were more 
likely to receive a methylphenidate prescription.  On the other hand, no significant association 
with maternal education was observed in children with ADHD symptoms. This finding might 
be interpreted that as long as the child has ADHD, there is no problem with inequity. When it 
comes to children without a diagnosis, there is inequity in treatment. Nevertheless, a previously 
published study showed that a low maternal education was associated with less involvement 
in the decision-making of medication initiation in children. Parents may not have sufficient 
knowledge about ADHD and feel that it is necessary to initiate methylphenidate when this is 
not thoroughly discussed with them [116].  Furthermore, we found that children whose mother 
had a western ethnic background who received a lower education, were more likely to receive 
methylphenidate than children whose mother received a high education. It may seem that only 
mothers with a western ethnic background with a low education are less likely to be involved. 
This association was not found in the non-western group. This may suggest that mothers with 
a non-western background, irrespective of educational level, are treated differently than moth-
ers with a western ethnic background.
Third, children with ADHD problems and their parents from ethnic minority groups may 
have less access to healthcare or less communication with healthcare professionals due to a 
language barrier [101, 117-121]. They may also receive less appropriate diagnoses or treatments 
as the symptoms observed for these disorders may differ across ethnic groups, and may differ 
from what clinicians are trained to expect [122, 123]. ADHD problems are also often recognized 
by teachers when children are more hyperactive than others. However, not all parents may 
consider hyperactivity as a behavioral problem as some parents may have a positive attitude 
towards a child with high energy [124]. This view and recognition of ADHD related problems 
may vary across different ethnic groups.  Furthermore, ethnic minority families may also be less 
likely to recommend medication and may prefer behavioral therapy over stimulant medication 
as found in previous studies [125, 126]. The findings of the current study may reflect cultural 
differences, knowledge and perceptions about ADHD and its pharmacological treatment.
Strengths and limitations
Strengths of our study are the relatively large population-based cohort, its prospective design, 
independent registration of dispensed medicines, and the multi-ethnic nature of the sample 
which limit the chance of selection and information bias. Treatment initiation was based on 
pharmacy dispensing records, which is more accurate in terms of dispensation date than infor-
mation on prescription medication from medical records or questionnaires as medication can 
be prescribed but not collected at pharmacies. However, our study also has some limitations. 
One of the limitations is that we had to rely on questionnaires filled out by mothers to as-
sess the presence of ADHD symptoms. These mother reports are considered valuable as they 
provide more insight into the perspective of the mothers with regard to their child’s behavior 
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as ADHD symptoms are not always recognized as such across different demographic groups. 
However, not all mothers completed the CBCL questionnaire, which is also considered as an 
important limitation as we were not able to assess the presence of ADHD symptoms in these 
groups. Information bias may have occurred if the association between maternal character-
istics or sociodemographic factors and treatment initiation is different for responders and 
non-responders, but this is difficult to ascertain. Nevertheless, the stratified analysis in the 
group without information on ADHD symptoms showed similar results for sex and ethnicity, 
except for maternal education. Another limitation is that pharmacy records were not available 
for half of the participants of The Generation R study as not all pharmacists provided consent 
to obtain the dispensing records from their pharmacies. As shown in the results, we found 
that mothers of children without pharmacy records differed on several aspects. Despite this 
selection bias, we observed similar results in our study compared to the available literature 
showing an association between initiation of methylphenidate and ethnicity, maternal edu-
cational level and smoking during pregnancy [116, 127]. Furthermore, no information about 
other treatment (e.g. behavioral therapy) was available. Therefore, we were not able to assess 
if specific demographic groups were not receiving therapy or were treated with behavioral 
therapy. Finally, information about maternal characteristics were not available for each child, 
but the non-response analysis showed no significant differences between both groups.
Conclusion
In conclusion, the current study showed that even when there are no reported ADHD symptoms, 
boys and children born to a mother of Dutch-Caucasian ethnicity or a low maternal education 
were  more likely to receive methylphenidate treatment.  This may suggest overtreatment. 
Considering these findings, it is important for healthcare professionals to be aware of these 
differences and take these into account when deciding on initiating treatment with methylphe-
nidate. Reasons for treatment initiation in children without ADHD symptoms should be further 
investigated.

4.2 Persistence and adherence to methylphenidate in children in the 
Netherlands
Cheung K, Dierckx B, El Marroun H, Hillegers MHJ, 
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AbstrAct
Background and objectives: Several studies have examined factors that may contribute to 
adherence and/or persistence to methylphenidate, but these were mainly conducted in adults 
and not in children. In children, determinants of adherence and are probably different from 
adults. However, information about the family and child characteristics in relation to adherence 
and persistence to methylphenidate treatment in children is limited. Therefore, the objective 
was to study determinants of adherence to and persistence of methylphenidate in children.
Methods: The study population included a subset of 307 children, from the population-based 
Generation R Study in the Netherlands, who all had at least one dispensing record of meth-
ylphenidate from birth up to the age of 16 years. Adherence was defined as a medication 
possession ratio (MPR) ≥ 0.80. Persistence was defined as duration of methylphenidate use 
until a discontinuation period ≥ 6 months. Family and child characteristics were tested as deter-
minants of adherence with multivariable logistic regression analysis. Persistence was evaluated 
using a Kaplan Meier analysis.
Results: Children of a nulliparous mother (adjusted OR: 2.31, 95%CI: 1.17-4.54) or a mother 
with an average household income (compared to high) were more likely to be adherent (ad-
justed OR: 3.45, 95%CI: 1.43-8.31). Girls were more often non-persistent than boys (adjusted 
HR: 1.44, 95%CI:1.07-1.95) and children who started treatment at age 12-16 were more often 
non-persistent than children who started before 12 years of age (adjusted HR: 3.55, 95%CI:2.54-
4.98).
Conclusion: In conclusion, the results of our study showed that both child and family charac-
teristics may play a role in methylphenidate treatment adherence. Furthermore, sex and age at 
start of the treatment was found to be associated with non-persistence. These findings may be 
important for healthcare professionals when initiating methylphenidate treatment in children.
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inTroduCTion
Methylphenidate is the first line pharmacological treatment option for attention deficit 
hyperactivity disorder (ADHD) as it is considered an effective pharmacological treatment in 
children[84]. However, for medication to be effective, compliance to treatment is crucial. Two 
important aspects of compliance are reflected by adherence and persistence. Adherence refers 
to the extent to which patients take medications as prescribed and persistence refers to con-
tinuing treatment for the prescribed duration . Various studies have shown that adherence and 
persistence to stimulant medication in children and adolescents is only 40 to 50% [128, 129]. 
Many studies investigating adherence and persistence  to methylphenidate were performed 
in adolescents and adults, whereas limited information is available in children [130, 131]. A 
previous study in adults, examined different sociodemographic factors that may contribute to 
adherence and persistence to methylphenidate treatment, and showed that male gender and 
a lower educational level were associated with discontinuation [132]. To investigate treatment 
adherence and persistence in children, it is important to consider also parental involvement 
as there are many parental factors that may contribute, such as socio-economic status and 
ethnicity [133]. A previous study that followed children with attention deficit hyperactivity 
disorder (ADHD) for 3 years, showed that pharmacological treatment was not accepted by all 
families [134], which may influence adherence and persistence to methylphenidate as parents 
are supposed to encourage children to continue to take their medication. However, the number 
of patients included in that study was small [134] and family or patient characteristics were 
not investigated.  For example, the age at treatment initiation may play a role as adolescents 
usually manage their own medication intake and could be more likely to forget or abstain from 
medication [135]. For school-aged children, parents usually make treatment decisions and 
have a greater influence on adherence and persistence to medication. Studies also showed 
that medication adherence was greater when both children and parents felt that symptoms im-
proved with treatment. The adherence and persistence may also be dependent on the dosage 
and the number of pills they have to take on a daily basis [130, 133, 136]. Finally, many studies 
have assessed adherence and persistence separately [135, 137-139]. However, it is important 
to assess adherence together with persistence, as they both are important aspects of adequate 
pharmacotherapy. For this reason, the objective of our study was to determine adherence to 
and persistence of methylphenidate treatment in children and to study potential determinants 
that were associated with these outcomes.
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MeThods
Study population
This study was conducted within the Generation R Study, a large population-based cohort study 
investigating children’s health from fetal life onwards in Rotterdam, the Netherlands [17]. All 
pregnant women from Rotterdam with a delivery date between April 2002 and January 2006 
were asked to participate in the study. Detailed and extensive data have been collected over the 
years which included interviews, questionnaires and behavioral observations of children and 
their parents [17]. In addition, pharmacy records of the children from community pharmacies 
from Rotterdam were retrieved. In the current study, all children (n=7,986) and their parents 
were invited to participate in the follow-up. Children were excluded if parents withdrew from 
the study (n=74), if no consent by parents was provided (n=1,084) or if the pharmacy did not 
consent to retrieve the pharmacy records, or because no pharmacy records were available in 
the pharmacy database (which may include non-users) (n=1,742). For 5,068 individuals in The 
Generation R Study, all prescriptions which were filled at their pharmacy during the entire study 
period were gathered. Of these, 6% (n=307) of children received at least one methylphenidate 
prescription and formed the study population (Figure 1 for flowchart). All methylphenidate-
using individuals were followed as of their first prescription until a) the end of the study period 
at 30 October 2018, b) loss to follow-up or c) end date of the last methylphenidate prescription, 
whichever came first.
Pharmacy records
Linkage between pharmacy records and Generation R participants was done at the community 
pharmacies in Rotterdam, but the information on methylphenidate use was extracted from 
automated pharmacy records, which was provided by the Dutch Foundation for Pharmaceutical 
Statistics [18].  For each dispensation, we collected the product name, Anatomical Therapeutic 
Chemical (ATC) code [102], date of filling, number of delivered tablets/capsules, and prescribed 
daily number. A methylphenidate dispensation was selected based on the ATC code N06BA04.
Methylphenidate use
Adherence was measured by the Medication Possession Ratio (MPR). The MPR measures the 
percentage of time a patient has access to medication and was calculated when children re-
ceived at least 2 prescriptions of methylphenidate. The MPR is the sum of days’ supply of meth-
ylphenidate during the follow-up period divided by the number of days in the that time period, 
i.e. between the first and end of the last prescription. According to international literature, a 
good adherence is set at an MPR of 0.80 or higher [129, 140]. Persistence of methylphenidate 
was calculated for all children who received at least one prescription of methylphenidate. 
Currently, there is no clear definition of non-persistence of methylphenidate treatment. In 
general, as previous studies used a gap period of 15 to 180 days as non-persistence [138, 139]. 
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Prescriptions for methylphenidate in the Netherlands are generally filled for 3 months. To 
ensure that no methylphenidate was dispensed after that, a gap period of 6 months (without 
prescription) was chosen for non-persistence.  Non-persistence was calculated starting from 
the calculated end date of the last prescription. Additionally, we collected information on the 
type of methylphenidate prescriber (specialist, general practitioner), as well as prescriptions 
of other psychotropic medication prior to the first methylphenidate dispensation, including 
anti-epileptics, antipsychotics, anxiolytics, hypnotics and sedatives, antidepressants or other 
ADHD medications (ATC code N06BA). We included the number of times the prescription was 
switched from short-acting methylphenidate to long-acting methylphenidate or vice versa and 
the number of prescriptions of short- or long-acting methylphenidate (number of long-acting 
prescriptions greater than short-acting or number of short-acting greater than long-acting).
Child characteristics and other determinants
Child characteristics that were considered as determinants of adherence, include age at 
first methylphenidate prescription (5-11 and 12-16 years), sex, ethnicity (Dutch , non-Dutch 
western, and non-Dutch non-western) [105],  and the presence of ADHD symptoms and other 
emotional and behavioral problems as reported by mothers using the Child Behavior Checklist 
Figure 1. Selection of study population  
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[103]. The Child Behavior Checklist (CBCL/1.5-5 and CBCL/6-18) was used to obtain information 
about behavioral and emotional problems in children [103]. The CBCL questionnaire has been 
filled out by the mother when the child was 3, 5 and 9 years old. The CBCL/6-18 was only 
used at the 9-years of age assessment. For the analyses, we used the most recently completed 
questionnaire prior to the first methylphenidate prescription. The CBCL contains items on the 
child’s behavioral and emotional problems which are scored on a three-point scale (0=not true, 
1=somewhat or sometimes true, 2=very or often true) during the preceding 2 months. There 
are five Diagnostic and Statistical Manual of Mental Disorders (DSM)-oriented scales: affec-
tive problems, anxiety problems, pervasive developmental problems, ADHD and oppositional 
defiant problems. It has been reported that these DSM-oriented scales provide accurate and 
supplementary information on clinical diagnosis with a good reliability and validity for the CBCL 
[104, 123].  We also measured the level of ADHD symptoms using the revised Conner’s’ Parent 
Rating Scales, (CPRS-R), which was filled out by primary caregiver at the age of 7-8 years. The 
CPRS-R consisted of 27 items that yielded several subscales: ADHD combined, ADHD Inatten-
tive, ADHD Hyperactive-impulsive and Oppositional Defiant Disorder Scale [141]. The score 
ranges from 0-18 for the ADHD inattentive, hyperactive-impulsive and oppositional defiant 
disorder and a possible score between 0-36 for the ADHD combined. Higher scores indicate 
more problems. Autistic traits were assessed using the Social Responsiveness Scale (SRS) short 
form [142].  Each item is rated from 0 to 3 (never true to almost always true), covering social, 
language, and repetitive behaviors. We used a cut-off defined as the upper 15% for the pres-
ence of autistic traits.
Family characteristics
We considered several family characteristics as potential determinants for adherence in chil-
dren: parity (1, >1), marital status (married, living together, no partner), maternal education 
(no/primary, secondary and high) and household income (low: ≤€2000, moderate: €2100-4000, 
high: €>4000). The demographic data was obtained using self-reports.
Analysis
Baseline characteristics were presented for all methylphenidate users with regular summary 
statistics.
First, determinants for methylphenidate adherence (MPR ≥0.80) at 2 years of follow-up 
(after receiving their first prescription) were assessed using logistic regression analyses to cal-
culate odds ratios (OR) and their 95% confidence interval (CI). For all determinants, we tested 
their independent association with adherence. Then, a multivariable logistic regression model 
was performed with all relevant determinants and confounders based on the literature (age, 
sex, ethnicity, type of prescriber, other psychotropic medication, number of short-acting and 
long-acting methylphenidate, number of switching, parity, marital status, maternal education 
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and household income) [136, 138, 143] to assess the association with the 2-years adherence. 
The MPR was only calculated for children who received at least 2 prescriptions.
Second, to evaluate the extent of medication non-persistence between a low (MPR lower 
than 0.50), moderate  (MPR between 0.50 and 0.79) and a high MPR (MPR of 0.80 and higher), 
we used unadjusted Kaplan-Meier curves. Statistically significant differences in methylpheni-
date persistence among children with a MPR<0.50, a MPR 0.50-0.80 and a MPR≥0.80 were 
identified using Wilcoxon tests. An extended Cox proportional hazards model was used to 
assess the risk of non-persistence adjusting for determinants.
Missing data of the determinants (ethnicity, type of prescriber, parity, marital status and 
household income) were imputed using multiple imputation (n=5)[144]. Missing data were only 
imputed if less than 30% of the specific variable was missing. Data of the child’s behavioral 
characteristics (CBCL, SRS and CPRS-R) were not imputed. Results were considered statistically 
significant at p<0.05. Statistical analyses were performed using IBM SPSS Statistics for Windows, 
version 21.0 (IBM Corp., Armonk, NY).
resulTs
Baseline
The characteristics of the study population and information about the dispensed medications 
are shown in Table 1. The mean age of  first methylphenidate prescription was 9.7 years and the 
majority of children receiving methylphenidate were boys (74.6%). Children were more often 
Table 1. Baseline child and family characteristics of children who have received a methylphenidate (MPH) 
prescription (n=307)
Child characteristic
Age at first methylphenidate prescription (years), mean (SD) 9.7 (2.4)
Sex
   Boy 229 (74.6)
   Girl 78 (25.4)
Ethnicity
   Dutch and other western 226 (73.6)
   Non-western 81 (26.4)
Type of prescriber of first methylphenidate prescription
   Specialist 274 (89.3)
   General practitioner 33 (10.7)
Other psychotropic medication prior to the first methylphenidate dispensationa
   No 276 (89.9)
   Yes 31 (10.1)
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Table 1. Baseline child and family characteristics of children who have received a methylphenidate (MPH) 
prescription (n=307) (continued)
Child characteristic
Short- and long-acting MPH
   Number of short-acting MPH per child, mean (SD) 9.7 (21.1)
   Number of long-acting MPH per child, mean (SD) 14.0 (22.7)
Number of times of switching between long- and short-acting stimulants
   0 174 (56.7)
   1 60 (19.5)
   2 or more 73 (23.8)
Affective problems (CBCL)b , mean (SD) 3.6 (4.4)
Anxiety problems (CBCL) b, mean (SD) 2.0 (3.7)
Pervasive developmental problems (CBCL) b, mean (SD) 2.1 (4.0)
Attention deficit/ hyperactivity problems (CBCL) b, mean (SD) 2.5 (4.3)
Oppositional defiant problems (CBCL) b, mean (SD) 2.1 (3.7)
Presence of autistic traits (SRS)c
   No 149 (48.5)
   Yes 58 (18.9)
Attention deficit hyperactivity disorder (CPRS)d, mean (SD) 15.6 (8.2)
Cognitive problems/ inattention (CPRS)d, mean (SD) 7.5 (4.7)
Oppositional defiant disorder (CPRS)d, mean (SD) 5.1 (3.6)
Hyperactivity (CPRS)d, mean (SD) 5.0 (4.1)
family characteristics
Parity
   1 169 (55.0)
   >1 138 (45.0)
Marital status
   Married, living together 249 (81.1)
   No partner 58 (18.9)
Maternal education
   No/ primary education 11 (3.6)
   Secondary education 145 (47.2)
   Higher education 151 (49.2)
Household income
   Low 61 (19.9)
   Moderate 125 (40.7)
   High 78 (25.4)
Values are given in numbers (%), unless stated otherwise. *Number of missing values are not shown. aanti-epileptics,  anti-
depressants, antipsychotics, anxiolytics, hypnotics and sedatives and melatonin.  bCBCL indicates Child Behaviour Checklist 
(CBCL/1.5-5 and CBCL/6-18)  cSRS indicates Social Responsiveness Scale short form. d CPRS indicates Conner’s Parent Rating 
Scale. Abbreviations: MPH indicates methylphenidate; N, number; SD, standard deviation.
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Dutch or had a western ethnic background (73.6%) compared to non-wester and the majority of 
our children received their first methylphenidate prescription from a specialist (89.3%). 10.1% 
of the children received other psychotropic medications prior to their first methylphenidate 
prescription. Finally, 18.9% of the children had autistic traits above the cut-off score.
Determinants of adherence
Table 2 shows determinants that were associated with adherence (MPR ≥0.80) to methylphe-
nidate treatment. Of the 264 children with more than one prescription, 63 were adherent 2 
years after treatment initiation. In the univariable analyses, we found that children more likely 
to be adherent when they mainly received  long-acting methylphenidate during the follow-up 
Table 2. Determinants associated with adherence (MPR ≥0.80) to methylphenidate treatment at 2 years after 
treatment initiation (n=264)*







Age at first methylphenidate prescription, years
   5-11 50 (79.4) Ref Ref
   12-16 13 (20.6) 0.66 (0.33-1.30)  0.75 (0.34-1.64)
Sex
   Boy 52 (82.5) Ref Ref
   Girl 11 (17.5) 0.58 (0.28-1.19) 0.54 (0.24-1.21)
Ethnicity
   Dutch and other western 54 (85.7) Ref Ref
   Non-western 9 (14.3) 0.39 (0.18-0.85) 0.50 (0.21-1.21)
Type of prescriber of first  MPH prescription
   Specialist 60 (95.2) Ref Ref
   General practitioner 3 (4.8) 0.39 (0.11-1.34) 0.38 (0.10-1.49)
Other medication before first  MPH prescriptiona
   No 54 (85.7) Ref Ref
   Yes 9 (14.3) 1.80 (0.76-4.28) 1.78 (0.66-4.81)
Short-acting and long-acting  MPH
   Mainly short-acting 20 (31.7) ref ref
   Mainly long-acting 43 (68.3) 2.50 (1.37-4.54) 2.01 (0.99-4.11)
Number of switching between long- and short-acting 
MPH
   0 23 (36.5) Ref ref
   1 11 (17.5) 1.12 (0.51-2.48) 1.15 (0.46-2.88)
   2 or more 29 (46.0) 3.15 (1.65-6.03) 2.35 (1.08-5.09)
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Table 2. Determinants associated with adherence (MPR ≥0.80) to methylphenidate treatment at 2 years after 
treatment initiation (n=264)* (continued)






Affective problems (CBCL)b 45 (71.4) 0.96 (0.89-1.04)
Anxiety problems (CBCL) b 58 (92.1) 0.92 (0.80-1.05)
Pervasive developmental problems (CBCL) b 58 (92.1) 1.05 (0.95-1.15)
Attention deficit/ hyperactivity problems (CBCL) b 57 (90.5) 1.00 (0.93-1.08)
Oppositional defiant problems (CBCL) b 58 (92.1) 1.03 (0.93-1.14)
Presence of autistic traits (SRS)c
   No 31 (49.2) Ref
   Yes 18 (28.6) 1.74 (0.86-3.51)
Attention deficit hyperactivity disorder (CPRS)d 42 (66.7) 1.01 (0.96-1.05)
Cognitive problems/ inattention (CPRS)d 42 (66.7) 1.00 (0.93-1.08)
Oppositional defiant disorder (CPRS)d 42 (66.7) 1.02 (0.92-1.12)
Hyperactivity (CPRS)d 42 (66.7) 1.07 (0.99-1.16)
family characteristics
Parity
   1 42 (66.7) 2.00 (1.10-3.66) 2.31 (1.17-4.54)
   >1 21 (33.3) Ref Ref
Marital status
   Married, living together 59 (93.7) Ref Ref
   No partner 4 (6.3) 0.26 (0.09-0.77) 0.26 (0.06-1.07)
Maternal education
   No/ primary education 2 (3.2) 1.04 (0.19-5.59) 1.83 (0.24-13.77)
   Secondary education 29 (46.0) 0.95 (0.50-1.81) 0.91 (0.42-1.97)
   Higher education 32 (50.8) Ref Ref
Household income
   Low 8 (12.7) 0.79 (0.28-2.23) 2.25 (0.46-11.05)
   Moderate 42 (66.7) 2.49 (1.20-5.17) 3.45 (1.43-8.31)
   High 13 (20.6) Ref Ref
Values are given in numbers (%), unless stated otherwise. * The MPR was only calculated when more than 2 prescriptions was 
received. **Number of missing values are not shown. ***The multivariable model included all variables except for the behav-
ioural characteristics. Determinants were selected based on the literature.  aanticonvulsants,  antidepressants, antipsychotics, 
anxiolytics, hypnotics and sedatives and melatonin.  bCBCL indicates Child Behaviour Checklist (CBCL/1.5-5 and CBCL6-18). We 
corrected for the time between the date the questionnaire was completed and the date of first prescription  cSRS indicates 
Social Responsiveness Scale short form. d CPRS indicates Conner’s Parent Rating Scale. Abbreviations: CI indicates confidence 
interval; N, number; OR, odds ratio; SD, standard deviation.
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period (OR: 2.50, 95%CI: 1.37-4.54). However, this association did not remain present in the 
multivariable analysis (adjusted OR: 2.01, 95%CI: 0.99-4.11). Also, children who switched their 
medication multiple times from short-acting to long-acting (and vice versa) were more likely to 
be adherent than those who did not switch (adjusted OR: 2.35, 95%CI: 1.08-5.09).
Further, children of  nulliparous mothers (adjusted OR: 2.31, 95%CI: 1.17-4.54) were more 
likely to be adherent. Compared to those with a high household income, we observed an as-
sociation between a moderate household income  and methylphenidate treatment adherence 
(adjusted OR: 3.45, 95%CI: 1.43-8.31). For the remaining determinants, including age of first 
treatment, sex, type of prescriber of first prescription, dispensation of other medications prior 
to the first methylphenidate prescription, maternal education and behavioral characteristics, 
no significant associations were found in the univariate or multivariate analysis.
Persistence
In total, 264 children were included in the survival analyses as they received more than one 
prescription for which the MPR could be calculated (43 children only received one prescrip-
tion). In the study population, 67 children had an MPR below 0.50 (25.4%), 125 children had 
an MPR between 0.50 and 0.79 (47.3%) and 74 children had an MPR of 0.80 or above (28.0%). 
The overall mean treatment duration until discontinuation was 2.7 years (SE: 0.14). In patients 
with an MPR <0.50, the mean treatment duration was 2.6 years (SE: 0.24), the mean treatment 
duration in patients with a MPR between 0.50 and 0.79 was 5.6 years (SE: 0.17), and  the mean 
treatment duration in patients with a good adherence (MPR≥0.80) was 3.1 years (SE: 0.33).
Figure 2 shows the survival curves of persistence in children with a low, (MPR <0.50), inter-
mediate (MPR 0.50-0.70) and a high adherence (MPR≥0.80). We found that children with a low 
or intermediate MPR had a higher persistence in the first 2.7 years of methylphenidate treatment 
(P<0.001). After 2.7 years, persistence was higher in children with a good adherence (P<0.001). 
Differences in survival curves between the three MPR groups were observed (p= 0.03).
Table 3 shows the risk of non-persistence in children who started methylphenidate treat-
ment. Only 4 children (1.3%) were persistent during the entire follow-up period. Girls were 
more likely to discontinue treatment than boys (adjusted HR: 1.44, 95%CI: 1.07-1.95). The risk 
of non-persistence increased with age (adjusted HR: 3.55, 95%CI: 2.54-4.98). Children who 
were more often prescribed short-acting methylphenidate than long-acting methylphenidate 
were more likely to be non-persistent (number of short-acting higher than long-acting, adjusted 
HR: 1.49, 95%CI: 1.13-1.96).
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disCussion
Main findings
This study aimed to investigate the adherence and persistence of methylphenidate treatment 
and their associated determinants. The current findings show that children who switched their 
medication multiple times from short-acting to long-acting (and vice versa) were more likely to 
be adherent than those who did not switch. Also, a number of family characteristics played a 




   <0.50 ref
   0.50-0.79 1.01 (0.74-1.38)
   ≥0.80 0.82 (0.56-1.19)
Sex
   Boy ref
   Girl 1.44 (1.07-1.95)
Age of first prescription
   5-11 years ref
   12-16 years 3.55 (2.54-4.98)
Ethnicity
   Dutch and other western ref
   Non-western 1.13 (0.83-1.53)
Type of prescriber of first MPH prescription
   Specialist ref
   General practitioner 1.26 (0.82-1.92)
Other medication before first MPH prescriptiona
   No ref
   Yes 0.91 (0.60-1.40)
Short-acting and long-acting MPH
   Mainly short-acting 1.49 (1.13-1.96)
   Mainly long-acting ref
Number of switches between long- and short-acting MPH
   0 ref
   1 1.05 (0.75-1.47)
   2 or more 0.77 (0.56-1.06)
*Adjusted for MPR, Sex, age of first prescription, ethnicity, type of prescriber, other medications prior to the first MPH prescrip-
tion, number of short-acting and long-acting methyphenidate and the number of switches between long-acting and short-
acting. aanticonvulsants,  antidepressants, antipsychotics, anxiolytics, hypnotics and sedatives and melatonin.  Abbreviations: 
CI indicates confidence interval; MPH, methylphenidate, N, number; OR, odds ratio; SD, standard deviation.
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role in the treatment adherence of children. We found that children whose mother had given 
birth to more than one child had a lower adherence and children from families with a moderate 
household income were more adherent than those with a high household income.
We found that girls were more likely to discontinue treatment than boys and that the risk 
of discontinuation increases with age. Furthermore, we found that children who were mainly 
using long-acting methylphenidate, were less likely to discontinue.
Explanation of these findings
First of all, it is important to emphasize that adherence in children is, unlike adolescents and 
adults, not only based on child determinants but also on parental factors. Parents play an 
important role in the medication adherence of children as they usually depend on them. We 
found that children whose mother gave birth to more than one child, were less likely to be 
adherent. As these children are mostly reliant on their parents, it is possible that mothers 
who have more than one child may find it difficult to make sure that their child follows the 
prescribed treatment regimen due to an overload of responsibilities and tasks (as they have 
to take care of more than one child) [145]. Furthermore, we found that children from families 
with an average household income were more likely to have a good adherence than those from 
families with a higher household income. Whether this is due to a higher household income 
where both parents are working and therefore have less time to monitor medication use in 
children, could not be studied. Further research is needed to investigate this observation. It is 
also possible that mothers with a higher household income are more ambivalent towards this 
type of pharmacotherapy [146].
Second, we found that after the 2.7 years, the persistence was higher in children with a 
good adherence compared to the lower ones. Children may stop using their medication due to 
adverse effects (e.g. problems with sleep or loss of appetite) or contra-indications and only take 
it when needed, resulting in discontinuity of treatment and thus a lower adherence [147]. They 
may also stop taking methylphenidate if they feel that the treatment does not work. Children 
who do not take their medication as prescribed (non-adherence) may eventually discontinue 
treatment as shown previously [137].
However, the question of whether patients are non-persistent or non-adherent may also 
be influenced by the fact that children are advised to have a medication-break (of one to two 
weeks) at least once a year. The Dutch Guidelines for General Practitioners describes that these 
breaks should be initiated to determine whether or not the pharmacological treatment should 
be continued, preferably during a representative period. However, in some cases it may only be 
possible to have these breaks during vacations and weekends [8].
Third, the results of our study show that girls were more likely to be non-persistent than 
boys, which was previously reported [138]. One of the possible reasons is that the effective-
ness of methylphenidate is easier to measure in boys in terms of symptoms improvement than 
girls, because boys more often show hyperactivity while girls more often have concentration 
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problems. When these symptoms improve, parents will probably encourage their children to 
take their medication according to prescribed treatment regimen [10, 113]. It is important to 
conduct further research to investigate the differences in non-persistence to methylphenidate 
treatment among boys and girls.
Finally, we found that children who started methylphenidate treatment at an older age 
were more likely to be non-persistent than those who started at a young age. This is in line with 
a previously published study where a younger age (0-8 years vs 10-19 years) was associated 
with greater persistence [138]. A possible explanation is that they may have used methylphe-
nidate (often short-term) for other reasons than treating ADHD symptoms, such as increasing 
school performance and are therefore less persistent [148]. However, the number of prescrip-
tions of short-acting stimulants in the young and older children was not significantly different. 
Another possible reason is that methylphenidate was prescribed for other indications such as 
oppositional defiant disorder (ODD), where methylphenidate may be less effective.
When considering long- and short-acting methylphenidate, our finding shows a greater 
persistence in children who mainly received long-acting methylphenidate, which is in line with 
a previous study [149]. Also, children who switched medication multiple times from long-acting 
to short-acting and vice versa, were more likely to be adherent than those who did not switch 
at all. It may be possible that they switch based on the severity of the disorder, but also the 
symptom improvement and adverse events may have played a role. This group may be more 
willing to try and find the best possible treatment and therefore are more likely to be adherent 
to treatment [150].
Strengths and limitations
One of the strengths of this study is the population-based cohort of young children with up 
to 16 years of follow-up and the multi-ethnic nature of this population. This long follow-up 
duration enabled us to investigate potential factors associated with adherence at 2 years 
(rather than 6 months as in previous studies)[135, 136]. Pediatric patients who started with 
methylphenidate may stop and restart again. Therefore, it is important to examine adherence 
at least 1 year after treatment initiation. Also, extensive information about the children and 
parents was collected prospectively since birth, which made it possible to assess numerous 
factors that are associated with a good treatment adherence. Furthermore, adherence and 
persistence were calculated based on dispensing records which is more accurate in terms of 
dispensation dates than information on prescription records as these medications may have 
been prescribed but not collected from pharmacies.
However, our study also has several limitations.  We did not have information on clinical 
diagnoses and relied on maternal reported questionnaire data on emotional or behavioral 
problems in the child.  Furthermore, we did not have information about other treatment such 
as behavioral therapy, which may have also influenced the persistence and adherence to meth-
ylphenidate. Also, the number of children in the older age groups is lower as for most children 
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in our study, they were followed until the age of 16 years. Therefore, the follow-up after treat-
ment initiation in the older children was shorter. However, persistence was only calculated in 
children when at least 7 months of follow-up was available after starting treatment to ensure a 
gap-period of 6 months (which is needed to measure non-persistence). Finally, we did not have 
sufficient power to assess the association between several determinants, such as child ethnicity 
and marital status with adherence as the numbers were too low. Further research in a larger 
population is needed to assess if and how ethnicity or marital status would affect adherence to 
methylphenidate in children.
Conclusion
In conclusion, the results of our study showed that both child and family characteristics may 
play a role in treatment adherence. Furthermore, child sex and start of treatment was found 
to be associated with persistence. Considering these findings, it is important for healthcare 
professionals to take these into account when initiating methylphenidate treatment.


4.3 Methylphenidate initiated during childhood is continued in adulthood in 
half of the study population
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AbstrAct
Background and objectives: Until the beginning of 2018, methylphenidate was only approved 
in the Netherlands for children between 6 and 18 years old, because of the cardiovascular risk 
in adults. Despite the fact that it was not approved for use in adults, there was a considerable 
degree of off-label use in this group. Therefore, the objective of this study was to estimate the 
number of patients who started methylphenidate during childhood and continued treatment 
beyond the age of 18 years and to study the determinants that may be associated with continu-
ing treatment.
Methods: Patients aged 17 years and younger who have received at least one prescription of 
methylphenidate were identified in the Integrated Primary Care Information (IPCI) database 
(1996-2017). Logistic regression analyses were performed to assess the association between 
potential determinants and continuation with methylphenidate treatment at the age of 18 
years.
Results: Fifty-three percent of all methylphenidate users (n=1,020) continued their treatment 
after the age of 18 years. Patients were more likely to continue treatment with methylpheni-
date if they started treatment at the age of 15 to 17 years compared to patients of 11 years 
and younger (adjusted OR: 5.74, 95%CI: 1.48-22.31), if they had a medication possession ratio 
(MPR) between 0.80 and 1.00 compared to a low MPR (adjusted OR: 2.18, 95%CI: 1.23-3.85) 
and if they lived in an area with a medium level of urbanization (adjusted OR: 1.98, 95%CI: 
1.06-3.69). Furthermore, a relatively high number of patients had a MPR greater than 1.0 (MPR 
> 1.0: 24.8%,) of whom 91.3% started their treatment when they were between 15 and 17 
years old.
Conclusion: Methylphenidate treatment initiated during childhood was continued in half of the 
study population when reaching the age of 18 where adolescents were more likely to continue 
treatment than young children. We also found that ~25% of our study population had a MPR 
greater than one, which may suggest misuse or abuse of methylphenidate.
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inTroduCTion
One of the most common neurobehavioral disorders is attention-deficit/hyperactivity disorder 
(ADD/ADHD), affecting approximately 5% of children worldwide and persisting into adulthood 
in the majority of the patients[3]. Stimulant medication such as methylphenidate is mostly 
prescribed as treatment for ADHD and the use of these drugs has increased over the past 
years[151]. Until the beginning of the year 2018, methylphenidate was only approved in the 
Netherlands for children between 6 and 18 years old because of the cardiovascular risk in 
adults[4]. This is also one of the most important reasons that this drug was not approved for 
use in adults as previous studies have shown that they may increase  heart rate and blood 
pressure and subsequently may lead to a slightly increased risk of myocardial infarction, sudden 
cardiac death, and stroke [5]. Despite the fact that it was not approved for use in adults, there 
was a considerable degree of off-label use in this group[21, 152]. Patients who have started 
ADHD drugs during childhood often continue treatment during adulthood, especially if they 
still suffer from symptoms and when the drug remains effective[137]. Previous studies have 
shown that approximately 60% of children with ADHD demonstrated persistence of symptoms 
into their mid-20’s [153, 154]. In 2015, there were more than 57,000 patients aged 25 and older 
who were using methylphenidate in the Netherlands [155]. A previous small study by McCarthy 
et al showed that almost half of the study population in UK (n=610) who started treatment 
in childhood were still on treatment at the age of 18 years or older[156]. They also found 
that the probability of persistence was lower in females than in males when methylphenidate 
was initiated at a younger age, but the opposite was observed when treatment was started in 
adolescence. However, the numbers in this study were low and it is not clear if there are also 
other determinants that might be associated with persistence.
Because of the cardiovascular risks in adulthood, it is important to investigate the deter-
minants of off-label use. Therefore, the objective of this study was to estimate the number of 
patients who started methylphenidate during childhood and adolescence and continued treat-
ment beyond the age of 18 in the Netherlands in the period before it was approved for use in 
adults. In addition, we studied the determinants of continuing treatment with methylphenidate 
at the age of 18 years.
MeThods
Setting
Data were obtained from the Integrated Primary Care Information (IPCI) database, a longitu-
dinal observational dynamic database containing medical records from more than 450 general 
practitioners (GPs) throughout the Netherlands. The study population is representative of the 
Dutch population and contains medical records of approximately 2,500,000 patients, including 
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longitudinal data on demographics, symptoms and diagnosis based on ICPC codes (International 
Classification of Primary Care) and free text, referrals, laboratory findings, discharge letters and 
drug prescriptions. All general practices in IPCI are fully automated and prescriptions contain 
details on product name, daily dosage, Anatomical Therapeutical Chemical (ATC)-code [19], and 
duration of use.  Details of the database have also been published elsewhere[20, 157].
Study population
The study population consisted of all patients with active follow-up during the study period be-
tween 1 January 1996 until 1 January 2017 having at least one year of medical records available 
and a prescription for methylphenidate during the study period. Patients were only included 
if they started methylphenidate before the age of 18 years and if they reached the age of 19 
years (to guarantee at least 1 year of follow-up during adulthood) before the end date of the 
study. The flowchart for children and adolescents included in the study is shown in figure 1. All 
patients were followed from study entry until the end date of the study.
Case definition
In this nested case-control analysis in a cohort of methylphenidate users, cases were defined 
as users of methylphenidate who continued use beyond the age of 18 years while controls 
were users who had used methylphenidate during childhood or adolescence but discontinued 
treatment before the age of 18 years.
Figure 1 Selection process of the study population 
 
 
Figure 1 Selection process of the study population
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Covariates
For each patient, we retrieved information from the IPCI database on covariates such as sex 
and age of first prescription of methylphenidate, the duration of use which was calculated from 
the start date of methylphenidate treatment until the end date of treatment or age of 18 years 
(whichever came first), the number of different types of ADHD drugs that were prescribed 
(such as dexamphetamine and modafinil) and the use of other psychotropic drugs before the 
age of 18. Furthermore, we also included the presence of any potential contraindications for 
use of methylphenidate namely the presence of cardiovascular and cerebrovascular disease 
(CVA, heart failure, myocardial infarction) and psychiatric disorders, such as alcohol and drug 
abuse, somatization disorder, psychotic symptoms, depression, anorexia nervosa, compulsory 
disorder, anxiety or suicide attempt. This comorbidity was assessed via disease specific ICPC 
code searches. We also considered medication adherence as a potential determinant which 
was measured by the medication possession ratio (MPR). The MPR was calculated by dividing 
the sum of the day’s supply of methylphenidate during the study period by the difference be-
tween the first and end date of the last. According to international literature, a good adherence 
is set at a MPR of 0.80 or higher [129, 140]. The MPR was only calculated if patients received at 
least 2 prescriptions of methylphenidate. Finally, we considered demographic information such 
as the living area: socially deprived area and the urbanization level as potential determinants.
Analysis
Within the study population, we conducted a case-control analysis. As potential determinants, 
we included sex, age of first prescription (<12 years, 12-14 years and 15-17 years),  MPR, number 
of different types of ADHD drugs before reaching the age of 18 years, use of other psychotropic 
drugs before the age of 18 and the presence of any potential contraindications in the database 
before starting treatment with methylphenidate.  We also included demographic information 
where we also considered the living area as potential determinants: socially deprived area (yes/
no) and urbanization level (very high: >2,500 addresses per km2, high: 1,500-2,500 addresses 
per km2, medium: 1,000-1,500 addresses per km2, low: 500-1,000adresses per km2 and not 
urban/rural: <500 addresses per km2). For the main analyses, we calculated the odds ratio 
(OR), with 95% confidence interval (CI) for each determinant associated with continuation of 
methylphenidate at the age of 18 years. We evaluated the potential determinants of continua-
tion of methylphenidate at the age of 18 years through univariable logistic regression analysis. 
In addition, a multivariable logistic regression analysis was performed including all univariably 
associated determinants. For those patients who continued treatment at the age of 18 years, 
we also determined the age when they will stop using methylphenidate. Results were con-
sidered statistically significant at P< 0.05. Statistical analyses were performed using IBM SPSS 
Statistics for Windows, Version 21.0 (IBM Corp., Armonk, NY).
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resulTs
In total, 47,380 patients were prescribed methylphenidate during the study period where 78% 
of these patients were older than 18 years (prevalent users or patients starting methylphenidate 
beyond the age of 18). This group was excluded together with those who were younger than 
19 years on the end date of the study (younger than 19 years, n=9,414). Overall, we identified 
1,020 patients who were prescribed methylphenidate before the age of 18 years of whom 
there were more males than females (males: 64.8% and females: 35.2%) (table 1). The major-
ity of the study population received their first methylphenidate prescription when they were 
between 15 and 17 years (86.9%). The majority of patients have been using methylphenidate 
for less than 6 months (55.5%), received one type of ADHD drug (90.9%), did not use any other 
psychotropic drugs before the age of 18 (87.3%) and did not have a contraindication before the 
start of treatment with methylphenidate (82.2%). Furthermore, the majority of patients lived 
in areas with a medium to high level of urbanization (very high: 12.2%, high: 24.6%, medium: 
18.4%, low: 7.4%, not urban/rural: 4.3%) and in a non-socially deprived area (yes: 5.5%, no: 
89.3%). We also observed that a relatively high number of patients had a MPR greater than 1.0 
(24.8%) compared to the number of patients with a MPR of 1.0 and lower (<0.50: 21.3%, 0.50-
0.79:21.2% and 0.80-1.00:13.9%). Of the patients with a MPR above 1 (n=253), the majority 
had a MPR  between 1.01 and 2.00 (n=209) and a small part had a MPR greater than 2 (n=44). 
When stratified for age, we observed that 91.3% of these patients with a MPR above 1 started 
their treatment when they were between 15 and 17 years old.
In the multivariable analyses, we found that patients who started treatment at the age of 
15 to 17 years were more likely to continue treatment with methylphenidate at the age of 18 
years (adjusted OR: 5.74, 95%CI: 1.48-22.31) (Table 2). People with a MPR between 0.80 and 




 Male 661 (64.8)
 Female 359 (35.2)
Agea
 <12 years 13 (1.3)
 12-14 years 121 (11.9)
 >14-17 years 886 (86.9)
Duration of use
 <6 months 566 (55.5)
 6-24 months 336 (32.9)
 >2 years 118 (11.6)
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1.00 were also more likely to continue treatment compared to those with a MPR below 0.50 
(adjusted OR: 2.18, 95%CI: 1.23-3.85). We also found that patients living in a medium level of 
urbanization were also more likely to continue use of methylphenidate beyond the age of 18 
years (adjusted OR: 1.98, 95%CI: 1.06-3.69). Patients who continued treatment beyond the age 
of 18 (n=542) received their last prescription for methylphenidate before the age of 21 (36.3%) 
and a small group stopped using methylphenidate when reaching the age of 25 (2.2%). For the 
majority of patients who continued treatment, it is not known at what age they received their 




 <0.50 217 (21.3)
 0.50-0.79 216 (21.2)
 0.80-1.00 142 (13.9)
 >1.00 253 (24.8)
Number of different ADHD drugsc
 1 927 (90.9)
 2 or more 93 (9.1)
Use of other psychotropic drugs before age 18
 No 890 (87.3)
 Yes 130 (12.7)
Potential contraindication before start ADHD drug
 No contraindication 838 (82.2)
 Cardiovascular diseases 25 (2.5)
 Psychiatric disordersd 157 (15.4)
Urbanisation level
 Very high 124 (12.2)
 High 251 (24.6)
 Medium 188 (18.4)
 Low 75 (7.4)
 Not urban/ rural 44 (4.3)
 Missing 338 (33.1)
Socially deprived area
 No 911 (89.3)
 Yes 56 (5.5)
 Missing 53 (5.2)
All numbers are given in numbers (%), unless stated otherwise. aAge of first prescription of methylphenidate. bMPR was only 
calculated for patients who received at least 2 prescriptions (n=828). cThe number of different ADHD drugs is based on the 
ATC7 codes. dPsychiatric disorders include alcohol and drug abuse, somatization disorder, psychotic symptoms, depression, an-
orexia nervosa, compulsory disorder, anxiety or suicide attempt. Abbreviation: MPR: medication possession ratio,  n:number
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Table 2 Determinants that are associated with continued use of methylphenidate at the age of 18 years 
(n=4,050)
Characteristic stopped Continued univariable analysis Multivariable analysis
n (%) (n=478) n (%) (n=542) or (95% Ci) or (95% Ci)*
Sex
 Male 318 (66.5) 343 (63.3) Ref Ref
 Female 160 (33.5) 199 (36.7) 1.15 (0.89-1.49) 1.39 (0.94-2.06)
Agea
 <12 years 10 (2.1) 3 (0.6) Ref Ref
 12-14 years 74 (15.5) 47 (8.7) 2.12 (0.55-8.09) 2.43 (0.60-9.93)
 15-17 years 394 (82.4) 492 (90.8) 4.16 (1.14-15.23) 5.74 (1.48-22.31)
MPRb
 <0.50 104 (29.1) 113 (24.0) Ref Ref
 0.50-0.79 93 (26.1) 123 (26.1) 1.22 (0.83-1.78) 1.30 (0.80-2.09)
 0.80-1.00 52 (14.6) 90 (19.1) 1.59 (1.03-2.46) 2.18 (1.23-3.85)
 >1.00b 108 (30.3) 145 (30.8) 1.24 (0.86-1.78) 1.22 (0.75-1.97)
Number of different
ADHD drugsc
 1 430 (90.0) 497 (91.7) Ref
 2 or more 48 (10.0) 45 (8.3) 0.81 (0.53-1.24)
Use of other psychotropic
drugs before age 18
 No 417 (87.2) 473 (87.3) Ref
 Yes 61 (12.8) 69 (12.7) 1.00 (0.69-1.44)
Potential contraindication
before start ADHD drugs
 No contraindication 396 (82.8) 442 (81.5) Ref
 Cardiovascular diseases 11 (2.3) 14 (2.6) 1.14 (0.51-2.54)
Psychiatric disordersd 71 (14.9) 86 (15.9) 1.09 (0.77-1.53)
Urbanization level
 Very high 65 (13.6) 59 (10.9) Ref Ref
 High 105 (22.0) 146 (26.9) 1.53 (0.99-2.36) 1.40 (0.79-2.49)
 Medium 68 (14.2) 120 (22.1) 1.94 (1.23-3.08) 1.98 (1.06-3.69)
 Low 36 (7.5) 39 (7.2) 1.19 (0.67-2.12) 0.98 (0.47-2.03)
 Not urban/ rural 19 (4.0) 25 (4.6) 1.45 (0.73-2.90) 1.35 (0.56-3.24)
Socially deprived area
 No 409 (85.6) 502 (92.6) Ref Ref
 Yes 34 (7.1) 22 (4.1) 0.53 (0.30-0.92) 0.76 (0.33-1.80)
All numbers are given in numbers (%), unless stated otherwise. *Sex and variables with P<0.05 in the univariable analysis were 
included in the multivariable analysis. aAge of first prescription of an ADHD drug (N06BA). b The MPR was only calculated if 
patients received at least 2 prescriptions of methylphenidate (n=828). cThe number of different ADHD drugs is based on the 
ATC7 codes. dPsychiatric disorders include alcohol and drug abuse, somatization disorder, psychotic symptoms, depression, an-
orexia nervosa, compulsory disorder, anxiety or suicide attempt. Abbreviation: CI: confidence interval, MPH: methylphenidate, 
MPR: medication possession ratio,  n:number
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last prescription of methylphenidate as the follow-up ended at the age of 19 years (and we do 
not know if they received a methylphenidate prescription after that) (61.4%).
disCussion
In this study, we found that a remarkably high percentage of patients older than 18 years were 
using methylphenidate. We also found that fifty-three percent of all methylphenidate users 
continued their treatment after the age of 18 years despite the fact that this was a relative con-
traindication as the drug was not licensed for use in adults during this study period. Previous 
studies have described concerns about cardiovascular safety in adult patients who are treated 
with methylphenidate [4, 158]. This drug was associated with an increased heart rate and blood 
pressure and previous studies have shown that even small increases in blood pressure and 
heart rate were associated with an increased risk of cardiovascular events [159-161] [162]. Fur-
thermore, we observed that the majority of patients started treatment with methylphenidate 
at the age of 15 to 17 years and were more likely to continue their treatment at the age of 18. 
This observation could be explained by the small number of patients who initiated methylphe-
nidate at a younger age. However, previous studies showed that the number of users in the 
Netherlands aged 16 years or older was increasing [163, 164]. It may appear that more severe, 
later onset youth were treated in our study. However, it is more likely that the first choice 
of long-acting stimulants in adults as opposed to the first choice of short-acting treatment in 
children may explain these findings as the long-acting stimulants are associated with increased 
adherence [165]. Despite the results where methylphenidate is more likely to be continued at 
15 to 17 years of age, we also observed that the majority of patients who continued treatment 
at the age of 18 (within the study period), stopped using methylphenidate when reaching the 
age of 21 and the remaining group stopped before the age of 25. Similar findings were observed 
in a previous study, where they stopped treatment by age 21[166]. Patients may stop treat-
ment when they experience less ADHD symptoms when reaching this age or because it was 
the patient’s decision to discontinue medication (dislike of taking medications or the feeling of 
being able to cope without pharmacological treatment) [137, 167, 168].
Methylphenidate treatment is mostly initiated during childhood and some patients con-
tinue to use it in adulthood as they may still suffer from ADHD symptoms [169]. In our study, 
we observed that methylphenidate was continued in 53% of all methylphenidate users which 
is higher than the number found in the study by McCarthy et al. (~40%) [156]. This may be 
explained by the differences in drug prescribing between both countries as the results of the 
study by McCarthy et al. also described higher estimates of ADHD drug prescribing in the Neth-
erlands than UK.  In this study they also found that the probability of persistence in females was 
lower compared to males when starting treatment at a younger age, however the opposite was 
observed in patients who started their treatment in adolescence [156]. In our study, relatively 
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more women were included compared to the previous study, but we did not find a significant 
association with continued use for the different age groups and gender.
The results of our study also showed that more than half of the patients stopped treatment 
within 6 months which is also the moment that  patients have to see their physicians as part 
of the regular monitoring process (cardiovascular status or worsening of psychotic symptoms) 
for those who started treatment with methylphenidate [8]. At that moment, patients may stop 
their treatment due the adverse events or because the drug was ineffective [170] [171]. An-
other possibility is that they may be misdiagnosed as having ADHD. Even though it is a condition 
that has been studied extensively, the causes of ADHD remain poorly understood, which makes 
it difficult to make a correct ADHD diagnosis [172].
It is not clear if the cardiovascular risks of these drugs are considered when deciding to 
stop or continue treatment with methylphenidate. We only found a small number of patients 
with cardiovascular disease in their medical history, but no significant associations were found.
In our study, we observed a relatively high number of patients with a MPR greater than 
1.0, especially in patients aged 15 to 17 years.  A MPR above 1.0 may indicate that patients 
are taking more than the prescribed dose, but it may also indicate stock piling due to early 
refills or vacation supplies[173]. However, it is also important to emphasize the possibility that 
methylphenidate was used for other reasons than for the treatment of ADHD [174]. A previous 
study has shown that the potential for abuse or misuse has increased along with the increase in 
prescribing frequency of methylphenidate [175]. Reasons for misuse of ADHD medication that 
were frequently reported are  to improve attention, concentration and alertness, to improve 
academic performances and they are misused recreationally [174, 175]. This may also be one 
of the explanations of the short-term use of methylphenidate in this age group as described 
earlier which may be related to the need for treatment in alleviating difficulties in education 
instead of taking methylphenidate to treat ADHD related symptoms [176]. These findings 
were also observed in a previous study conducted in Sweden [177] . Furthermore, a previous 
study showed that misuse of short-acting methylphenidate is also more common than with 
the long-acting methylphenidate [178]. The fact that only the short-acting methylphenidate 
is fully reimbursed in the Netherlands may have also influenced this. These data suggest close 
monitoring of methylphenidate use and dispensation of these drugs, in particular to patients 
aged 15 years and higher.
The main strength of our study is that we had access to a large real life population-based 
cohort with detailed information on drug prescriptions and co-morbidities over a long period 
of time.  Furthermore, selection bias in our study is not likely as almost all inhabitants in the 
Netherlands are registered with one GP where data are collected as part of routine patient 
care, irrespective of a research question. However, our study also has several limitations. Firstly, 
there was no information available on dispensing by the pharmacy nor on actual drug intake. 
Secondly, we do not have (complete) information about the severity of the disease and there-
fore we may have included the less severe cases of depression or other disorders where the use 
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of methylphenidate is contraindicated. Furthermore, the database may miss the prescriptions 
that are directly written by medical specialists. This database mainly contains GP prescriptions 
and also prescriptions that are initiated by the specialist and continued by the GP, but it is 
possible that not all prescriptions by medical specialists are captured in the database. However, 
in the Netherlands it is common practice for GPs to continue prescriptions when initiated by 
medical specialists, especially if it concerns drugs for chronic use. There is also the potential of 
selection where especially older children are selected as the median active follow-up time in 
IPCI is relatively short (mean: 6.8 years, SD: 2.0 years) as our study only selected children who 
were followed until at least the age of 19 years. Previously published articles showed that the 
number of methylphenidate dispensations among people of 15 years and older have increased 
in the Netherlands and in other European countries (UK, Denmark and Germany) [6, 179, 180]. 
Furthermore, the lack of objective measures of ADHD and the changes over time may have 
influenced the findings as we did observe a higher percentage of patients continuing treatment 
beyond the age of 18 years in the period 2012-2016 compared to the previous 5 years. This can 
be explained by the increased ADHD recognition and treatment and the change in different 
prescribing patterns among different age groups and gender [180, 181]. Because these changes 
also occurred in other western countries, we think that our results can be generalized to many 
of these countries. ADHD diagnosis and treatment with medication may be more accepted in 
the future by the general population as the attitude of parents and children towards ADHD has 
also changed. Treatment with medication can be considered by parents as a way to improve 
their child’s achievements and performance at school. Also the children themselves may feel 
the need to use psychostimulants to improve their performance at school [182]. Furthermore, 
it is possible that treatment in girls may also increase in the future as ADHD diagnosis in this 
gender group may improve over time [10].
Conclusion
About half of the patients who were prescribed methylphenidate during childhood and ado-
lescence continued their treatment in adulthood which was considered as off-label use until 
recently. The majority of this population started their treatment in adolescence, which may 
explain the reason for continuing treatment at the age of 18 years. We also found that ~25% 
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Background and objectives: The existing literature provides contradictory evidence on antide-
pressant use and risk of suicide. Some studies have shown that the use of Selective Serotonin 
Reuptake Inhibitors (SSRIs) is associated with an increased risk of suicide, especially during 
the first months of treatment, whereas other studies did not confirm this association. For this 
reason, our objective was to investigate the association between antidepressant use and risk of 
suicide in incident antidepressant users in relation to time since starting therapy.
Methods: We conducted a population-based cohort study within the Dutch Integrated Primary 
Care Information (IPCI) database, in incident users of antidepressant therapy between 1994 
and 2012 (n=27,712). Cox proportional hazard models were used to study the association 
between current use of SSRIs, tricyclic antidepressants (TCA) and other antidepressants and 
risk of suicide or attempted suicide.
Results: During follow-up, a total of 280 incident antidepressant users attempted or commit-
ted suicide. Current use of SSRIs (hazard ratio (HR): 0.78, 95% CI: 0.57-1.07), TCAs (HR: 0.82, 
95% CI: 0.48-1.42) or other antidepressants (HR: 0.75, 95% CI: 0.47-1.18) was not statistically 
significantly associated with suicide compared to past use of any of the antidepressants.
Conclusions: This study did not indicate an increase in risk of suicide after starting treatment 
with SSRIs, TCAs or other antidepressants compared with past antidepressant use.
Chapter 5.1 101
Antidepressant use and the risk of suicide: a population-based cohort study
inTroduCTion
Suicide accounts for almost one million deaths worldwide each year and is therefore a major 
problem in many countries [183]. Depression is the most important risk factor [184]. From the 
various treatments that are available to treat depression, Selective Serotonin Reuptake Inhibi-
tors (SSRIs) are prescribed most frequently [185]. This preference to prescribe SSRIs, compared 
to tricyclic antidepressants (TCAs), is due to their milder adverse effect and toxicity profile 
[186]. Compared to non-use as well as compared to TCAs and other antidepressants, SSRIs were 
associated with an increased risk of suicidal behaviour, especially in children and adolescents 
[187-189]. The risk seems to be increased especially during the first month of therapy [188, 
190]. As a causal pathway, it is hypothesized that SSRIs may cause agitation and subsequently 
potential ill-considered behaviour, before their beneficial effect relieves depression [191]. 
However, others could not confirm the increased risk of suicide during use of SSRIs [192-194]. 
It therefore remains controversial whether SSRI use is associated with suicidal behaviour. For 
studies comparing SSRIs and TCAs, findings might be influenced by confounding by indication, 
as indications for prescribing TCAs and SSRIs are different [195, 196].
Because of the lack of consistency between studies and the limitations of some of these, 
our objective was to investigate the association between incident use of antidepressants and 
the risk of suicide or suicide attempts in a large population-based study with prospectively 
gathered healthcare information, under the hypothesis that the risk of suicide would be higher 
during the first weeks of treatment with SSRIs,  TCAs or other antidepressants.
MeThods
Setting
Data from the Integrated Primary Care Information (IPCI) database were used. The IPCI database 
contains computer-based patient records of more than 600 Dutch General Practitioners (GPs). 
In the Dutch healthcare system, the GP acts as the gatekeeper of all individual healthcare infor-
mation and all inhabitants are registered with a GP. The IPCI database currently contains patient 
information of 1.5 million subjects, including age, sex, date of birth, symptoms, diagnoses, 
laboratory results, summaries of specialist letters and drug prescription data. Drug prescrip-
tion data, included product name, quantity prescribed and dosage regimen. The International 
Classification of Primary Care (ICPC) coding system is used to code diagnoses [20, 157, 197]. 
We used the Anatomical Therapeutic Chemical (ATC) classification scheme to classify drugs 
that were prescribed to patients.  The IPCI database follows the European Union guidelines on 
the use of medical data for medical research and has been validated to be used for pharmaco-
epidemiological research. The scientific and ethical advisory board of the IPCI project approved 




The study population comprised all patients with an incident antidepressant prescription be-
tween 1994 and 2012 who had ≥1 year of data registered in the database before entering the 
study. Patients were followed from the date of first antidepressant drug prescription (baseline) 
until their first attempted suicide, completed suicide or end of the study period on 1 February 
2012 whichever came first. We excluded patients under the age of 10, patients with a recorded 
diagnosis of a psychotic disorder (ICPC code P71) and patients who had multiple different anti-
depressant drug classes dispensed on the same day. Patients who received an antidepressant 
prescription 6 weeks prior to the end of the study period were excluded, to ascertain that 
everybody had at least 6 weeks of follow-up.
Outcome measures
The study outcomes were defined as a notification of either a completed suicide or as an 
attempted suicide, either coded as P77 (ICPC code ‘suicide’) or p77.01 (ICPC code ‘suicide at-
tempt’), or as similar free text through automated text search. All cases identified with the 
automated text search were validated manually using the electronic medical records. The first 
date of suicide or suicide attempt served as the index date.
Exposure definition
The exposure of interest was antidepressant drug use. We categorized these drugs into three 
classes based on ATC code (4th level): TCAs (N06AA), SSRIs (N06AB) and other antidepressants 
(N06AG, N06AF and N06AX). Throughout the follow-up time, each individual could provide 
person-time to one or more periods of current or past exposure over the course of the study 
period. Patients were classified as currently or previously exposed to an antidepressant, based 
on the exposure status on the index date. If the date of event fell between the start date and 
end date of an antidepressant prescription, these patients were considered as current users. If 
the index date was after the last date of prior antidepressant use, the patient was considered 
a past user.
Co-variables
Several co-variables were considered as potentially confounding factors: year of first antide-
pressant prescription, indication for antidepressant use (at date of first antidepressant pre-
scription and at index date), age, sex, history of previous suicide attempts, history of self-harm 
(both within 1 year prior to the date of first antidepressant prescription), psychotropic drug 
use at index date (antipsychotics: ATC-code N05A, anxiolytics: N05B, hypnotics and sedatives: 
N05C) and sequential use of different antidepressants (switching). The latter was considered 
as a potential risk factor, as some patients may be resistant to antidepressant medications 
possibly indicating a more severe depression. The indication for antidepressant drug use was 
identified through the diagnoses in the medical records and includes the following indications: 
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depression (ICPC code P76 and P03), anxiety (P01 and P74) and depression and anxiety com-
bined. We used the ICPC codes and corresponding free text to identify patients with depression 
using an automated text search. When the indication was not grouped in the above mentioned 
categories, the indication was stated as ‘other indication’. A subsample was validated manually 
to determine whether the automated text search correctly identified ‘depression’ and ‘anxiety’ 
as the indications for antidepressant use.
Statistical analyses
A Cox proportional hazards model was used to estimate hazard ratios (HRs) and their 95% 
confidence intervals (CIs) for the associations between the use of different antidepressants and 
suicide or suicide attempt [110]. Use of antidepressants was included in the model as a time-
varying determinant. Co-variables were included in the multivariable model if they changed 
the point estimate of the association between antidepressant use and suicide > 10 percent or 
were considered clinically relevant. Sub-analyses were performed to investigate whether the 
risk varied in relation to time since starting therapy (1-14 days, 15-28 days and >28 days).  To 
evaluate potential confounding by indication, we investigated current antidepressant use in 
depressed patients and current use for other (unknown) indications separately. Dose response 
analyses were performed to assess whether the risk varied between high and low dose of 
antidepressant use. A low dose was defined as the median dose or less and a dose higher 
than the median dose was defined as a high dose. Analyses with regard to the duration of past 
use were performed to assess whether this influenced the risk of suicide in our population. In 
the analyses, we took less than 1 year and more than 1 year past use as separate reference 
groups. In another sub-analysis potential effect modification by age and sex was tested, strati-
fied analyses were presented accordingly. All analyses were performed using SPSS version 21.0 
(IBM Corporation, Armonk, NY). P-values below 0.05 were considered statistically significant.
resulTs
Baseline characteristics
Table 1 describes the baseline characteristics of the study population. A total of 27,712 patients 
were identified as having received an antidepressant drug prescription, of whom the majority 
were women (61.2%). SSRI users tended to be younger (median: 44 years, IQR: 42.0 – 70.0) 
than those prescribed TCAs (median: 55 years, IQR: 28) and SSRI users comprised the largest 
group of patients for whom a diagnosis of depression was registered (37.6%) compared to TCAs 
(7.3%) and other antidepressant types (19.4%).
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Associations between known risk factors and suicide
In the total population with 280 cases, we found that a history of self-harm (HR: 6.94, 95% CI: 
4.53-10.64) and psychotropic drug use (HR antipsychotics: 6.42, 95% CI: 4.19-9.85, HR anxiolyt-
ics: 5.07, 95% CI: 3.78-6.79, HR hypnotics and sedatives: 4.33, 95% CI: 3.05-6.15) were the 
strongest factors associated with the risk of a suicide (attempt) (table 2). Age, in particular 
between age 10 to 24 years (HR: 6.41, 95% CI: 3.76-11.06), was also found to be strongly as-
sociated with the risk of a suicide attempt. Other factors that were significantly associated 
with suicide were different antidepressant prescriptions (switching antidepressants) (HR: 2.38, 
95% CI: 1.69-3.34) and depression (HR: 2.53, 95% CI: 1.82-3.50). A higher risk was observed 
for patients diagnosed with both depression and anxiety at the same time (HR: 4.40, 95% CI: 
1.92-10.1).
Table 1 Characteristics of study population at baseline according to first antidepressant type prescribed













 10-24 2,169 (7.8) 399 (5.2) 1,305 (10.3) 465 (6.4)
 25-40 7,388 (26.7) 1,364 (17.6) 4,082 (32.2) 1,942 (26.6)
 41-55 8,442 (30.5) 2,179 (28.2) 3,721 (29.3) 2,542 (34.9)
 56-70 5,187 (18.7) 1,953 (25.3) 1,820 (14.3) 1,414 (19.4)
 >70 4,526 (16.3) 1,837 (23.8) 1,758 (13.9) 931 (12.8)
Mean age (SD) 49.6 (17.9) 55.3 (18.3) 46.7 (18.5) 49.1 (16.9)
Sex, female 16,970 (61.2) 4,916 (63.5) 8,001 (63.1) 4,053 (55.6)
Indication of use
 Depression 6,752 (24.4) 564 (7.3) 4,774 (37.6) 1,414 (19.4)
 Anxiety 1,103 (4.0) 191 (2.5) 655 (5.2) 257 (3.5)
 Depression and
 anxiety




19,151 (69.1) 6,923 (89.5) 6,746 (53.2) 5,482 (75.2)
History of self-harm a 257 (0.9) 24 (0.3) 173 (1.4) 60 (0.8)
Use of psychotropic drugs
 Antipsychotics 484 (1.7) 83 (1.1) 264 (2.1) 137 (1.9)
 Anxiolytics 2069 (7.5) 381 (4.9) 1190 (9.4) 498 (6.8)
 Hypnotics and
 sedatives
1523 (5.5) 388 (5.0) 733 (5.8) 402 (5.5)
Values are given in numbers (percentages) unless stated otherwise. a Referred to as self-injury or previous suicide attempts, 
prior to date of first antidepressant prescription. Abbreviations: n; number of antidepressant users, TCAs; tricyclic antidepres-
sants, SSRIs; Selective Serotonin Reuptake Inhibitors
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Association between antidepressant treatment and suicide (attempt)
Table 3 shows the association between current antidepressant use and suicide (attempt). We 
observed no significant associations with suicide in patients who were prescribed SSRIs (HR: 
0.78, 95% CI: 0.57-1.07), TCAs (HR: 0.82, 95% CI: 0.48-1.42) or other antidepressants (HR: 0.75, 
95% CI: 0.47-1.18), compared to past use, after adjustment for the known risk factors (age, sex, 
indication of use, antipsychotic use, anxiolytic use and number of different antidepressants 
prescribed). We also found no evidence of a higher suicide risk in patients prescribed TCAs 
currently (HR: 0.89, 95% CI: 0.26-3.06), SSRIs (HR: 0.56, 95% CI: 0.31-1.09) or other antidepres-
sants (HR: 0.54, 95% CI: 0.20-1.45) when restricted to the indication of depression. When strati-
fied by age or gender, no significant differences for the different strata was observed (results 
not shown). Patients treated with TCAs receiving a high dose compared to low dose were at 
a higher risk of suicide (HR: 3.52, 95% CI: 1.04-11.93, p-value: 0.043). In patients treated with 
Table 2  Hazard ratios of potential risk factors for suicide and suicide attempt
Variable Cases, n hr (95% Ci) c P
Age, years
 10-24 50 6.41 (3.76-11.06) <0.001
 25-40 90 2.87 (1.73-4.76) <0.001
 41-55 107 2.68 (1.62-4.41) <0.001
 56-70 38 1.58 (0.90-2.76) 0.11
 >70 18 1 (ref)
Sex, femaleb 182 0.92 (0.73-1.16) 0.47
Indication for antidepressant
 Depression 54 2.53 (1.82-3.50) <0.001
 Anxiety 7 1.66 (0.78-3.56) 0.19
 Depression and anxiety 6 4.40 (1.92-10.06) <0.001
 Unknown/other indication 236 1 (ref)
History of self-harm a,b 23 6.94 (4.53-10.64) <0.001
Concurrent use
psychotropic drugs b
 Antipsychotics 23 6.42 (4.19-9.85) <0.001
 Anxiolytics 59 5.07 (3.78-6.79) <0.001
 Hypnotics and sedatives 38 4.33 (3.05-6.15) <0.001
No. of antidepressant
types prescribed during follow-up
 1 253 1 (ref)
 >1 50 2.38 (1.69-3.34) <0.001
a Referred to as self-injury or previous suicide attempts, prior to date of first antidepressant prescription. b Reference group: 
male, no history of self-harm and non-use for psycholeptics. c Adjusted for age and sex. Age was adjusted for gender and gen-
der was adjusted for age only. Abbreviations: HR; Hazard rate ratio, CI; confidence interval, n; number of cases with completed 
suicide or suicide attempt, P; p-value
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SSRIs, no significant differences were observed between high and low dose (HR: 1.44, 95% CI: 
0.61-3.39, p-value: 0.409). We did not observe differences in suicide risk between the analyses 
where we took a reference group of less than 1 year and more than 1 year past use (results not 
shown).
Analyses by duration of antidepressant use
Figure 1 shows the association between SSRIs and suicide risk in relation to time since starting 
therapy. Although a higher risk was observed in patients who recently started therapy with 
SSRIs (HR 1-14 days, adjusted for age and sex: 1.44, 95% CI: 0.96-2.17), this did not reach 
Table 3  Risk of suicide in patients prescribed SSRIs, TCAs and other antidepressants
Total population depression only








Past use a 202 1 (ref) 1 (ref) 27 1 (ref) 1 (ref)































Suicide risk by indication. a Includes use of all antidepressant types. b Model 1: adjusted for age and sex. c Model 2: adjusted 
for sex, age, antipsychotic use at index date, anxiolytic use at index date, indication at index date and the number of different 
antidepressants prescribed during follow-up. d Adjusted for all the above mentioned risk factors except for the indication at 
index date. Abbreviations: HR; Hazard rate ratio, CI; confidence interval, n; number of cases with completed suicide or suicide 
attempt, P; p-value, TCAs; tricyclic antidepressants, SSRIs; Selective Serotonin Reuptake Inhibitors




Figure 1 SSRI treatment duration and risk on suicide (attempt)
Current treatment with SSRIs compared to past use of all antidepressant types. Model 1: adjusted for age and sex. Model 2: 
adjusted for sex, age, antipsychotic use at index date, anxiolytic use at index date, indication at index date and the number of 
different antidepressants prescribed during follow-up. Abbreviations: SSRIs, Selective Serotonin Reuptake Inhibitors; d, days.
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statistical significance. After adjustment for the other factors, we observed no increased risk in 
patients who recently started SSRIs (HR 1-14 days: 0.79, 95% CI: 0.51-1.21, HR 15-28 days: 0.75, 
0.46-1.24 and HR >28 days: 0.76, 0.41-1.40). Similar results were observed for patients who 
were prescribed TCAs or other antidepressants, but with wider confidence intervals due to low 
numbers of cases (results not shown).
disCussion
The objective of the current study was to assess the association between the use of different 
antidepressant drug classes and the risk of suicide or suicide attempt during the first weeks of 
treatment. The results of our study did not show an association between the different antide-
pressant drug classes and suicide (attempts) overall nor during the first weeks of treatment. In 
addition, we did not observe an increased risk in the initial treatment period nor did we find 
an increased risk when restricting analyses to specific indications. We also found no significant 
effect modification by age and gender. Previous studies yielded similar results [6, 21]. Patients 
receiving a high dose of TCAs compared to low dose were at a higher risk of suicide. A possible 
explanation is that these patients suffer from a more severe depression, which is associated 
with an increased risk of suicide [198]. Also, depressed patients use TCAs for self-poisoning or 
suicide [199].
In line with currently available literature, we found that classical risk factors, such as young 
age, depression, a history of self-harm, antipsychotic use (as a crude measure of a psychotic 
indication) and sequential use of different antidepressants were associated with a higher risk 
of suicide (attempts) [187, 191, 195, 200-202]. Previous researchers observed an increased risk 
of suicide with SSRI use in young individuals [187, 203, 204]. Although it might therefore be 
speculated that the risk of suicide in SSRI users is age dependent, age did not act as an effect 
modifier in our study, suggesting that risk was similar between low and high age. However, our 
study population consisted largely of patients aged 25 and over (92.2%), leaving only a limited 
number of patients aged 25 years or younger. In contrast to our results, another study observed 
an increased risk of suicide in patients with depression prescribed SSRIs, TCAs or other antide-
pressants compared with no current treatment [205].  A possible explanation for the lower risk 
of suicide is that ‘no current treatment’ may indicate no depression or less severe depression 
than being under treatment. Confounding by indication in the previous studies might underlie 
this difference in observation, as these studies did not adjust for the indication of treatment 
[195, 205].
Previously, an increased risk of suicidal behaviour during the first month of SSRI therapy 
compared with other antidepressants was found [195]. However, others could not confirm this, 
as the risk was found to be highest in the month before the initial prescription (because suicide 
attempt may prompt initiation of antidepressant treatment) and a decline in risk after initiation 
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of treatment [206]. In our study, estimates for the first weeks of use did not differ significantly 
from longer durations of use. Although it is likely that the duration of past use may influence 
the risk of suicide, this did not change the risk in our study population. We did not find an in-
creased risk in current users compared with past users of less than one year nor did we find an 
increased risk in current users compared with past users of more than one year.  Therefore we 
suggest that the risk is similar in both reference groups. A possible biological mechanism that 
might explain the phenomenon of increased suicidal risk in the first weeks after start of SSRIs 
may be the slow onset of drug action in patients with severe depression [207]. The serotonin 
levels may increase before the depression is relieved, presumably by down regulation of the 
postsynaptic receptor population [208]. Therefore, patients may transiently become extremely 
agitated and restless and commit suicide before the drug treatment starts to relieve depression 
[191, 207, 209]. Patients may also become more anxious following onset of SSRI treatment, 
which is also associated with an increased risk of suicide [210]. Our results did not support the 
findings of these previous studies [188, 190], as we did not find evidence or differences in risk 
of suicide in relation to time since starting therapy. A possible explanation for this finding is 
that the population used in this particular analysis, where we stratified by treatment duration, 
was not restricted to patients with depression only. The number of cases was too small to make 
precise estimates in this analysis.
Strengths and limitations of the study
An advantage of our study is the large number of GPs participating in the IPCI project, providing 
us with complete medical information of at least 1.5 million patients. In the Dutch healthcare 
system, the GP acts as the gatekeeper of all individual healthcare information. Consequently, 
there was information on drug use and potential confounders available. With this information 
we were able to assess the use of antidepressants and the potential confounders at different 
time points. A key advantage of this cohort design is that we were able to include all eligible 
incident antidepressant users, which minimizes the risk of selection bias.  Also, in our opinion, 
the information bias is minimal as we used prescription records as the source of medication 
data [28, 211].  However, patients whose antidepressant treatment was initiated by a specialist 
(prior to cohort entry) may have been misclassified as the IPCI database largely consists of GP 
prescription data and it does not include information about whether prescribed medications 
are actually taken by the patient. However, we expect that the actual intake of antidepressant 
drugs will be non-differential between the different drug classes. We manually validated all po-
tential suicide cases and grouped those who did not have a recorded suicide or suicide attempt 
in the control group and therefore minimizing the risk of misclassification of the outcome. 
Our study also has several limitations. Several studies have demonstrated that patients with a 
greater risk of suicide or self-harm (often with a recorded history of self-harm) are preferably 
prescribed SSRIs, since this antidepressant class is safer when taken in overdose than TCAs [196, 
212]. As the number of history of self-harm cases in our study was low, it is likely that we were 
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not able to extract all cases of self-harm prior to start of therapy. Another observation is the 
relatively high number of patients with an indication for antidepressants other than depression 
or anxiety. We assumed that not all patients with depression were recognized as such, because 
we restricted only to synonyms for depression, and not for keywords of symptoms in the auto-
mated text search. We manually validated a subsample to determine whether the automated 
text search correctly identified ‘depression’ and ‘anxiety’ as the indication for antidepressant 
use.  We found similar results for depression (47.3%) and anxiety (10.3%) as was found earlier 
[213]. It could be speculated that the change in the prescribing practices over the last 20 years 
may have affected our results. However, we believe that this is not an issue in our study as the 
majority of our study population received their first antidepressant prescription after 1 January 
2000 (90.5%). We also included the year of first antidepressant prescription in the model as a 
confounding factor, but this did not change the risk of suicide (attempt). A recently published 
study showed that the number of cases of suicide and self-harm that was not reported in the 
UK health care database was relatively high, which may also be considered as a limitation in our 
study [214]. However, we expect that under-reporting of suicide attempts between different 
antidepressant drug classes will be non-differential.
Conclusion
In summary, we did not find evidence for an increased risk of suicide or suicidal attempts in the 
first weeks of treatment in patients who were treated with SSRIs, TCAs or other antidepressants 






General disCussion and fuTure PersPeCTiVes
Over the past years, we have been conducting observational research using different databases 
with data collected over the years. Such databases have become larger over the past decade 
thanks to the increasing computerization of healthcare, containing more detailed information 
about medication use and diseases in individuals and over longer periods of time. Many data-
bases can nowadays be linked to each other to study specific associations between exposures 
and outcomes, such as the linkage between health registers containing data on persons with 
diseases or health-related events and pharmacy record databases. Of course, only when linking 
takes into account current legislation and individual privacy. These observational studies using 
big databases are becoming more and more important as they are able to answer questions 
which could not be answered by clinical trials due to the homogeneous population and small 
sample sizes in these trials. These observational studies also enable us to investigate when and 
why certain medications are prescribed.
In this chapter, key findings will be discussed as well as how it relates to the existing 
knowledge and the currently available literature. The following two main topics will be further 
elaborated, where the clinical relevance of the findings in this thesis will be discussed:
1. Information captured in the different databases
2. Pharmacological treatment, is it always the best solution?
inforMaTion CaPTured in The differenT daTabases
Pharmacy records vs medical records vs reported data – advantages and 
limitations
In observational studies, one can perform field studies but this approach is cumbersome and 
expensive. Therefore, we used many different types of databases. Databases can be different 
due to the type of population included or the information that is available. They each have 
their strengths and limitations, and the decision to choose one particular type is often based 
on the research question we intend to answer and the question whether the type of data 
that are needed, are available. For the results of this thesis, we have used different sources of 
information which are outlined below.
In chapter 3.1, information from the Dutch Foundation for Pharmaceutical Statistics was 
used, which contains dispensing data from more than 97% of all community pharmacies in the 
Netherlands. One of the main strengths of this database is its large size and the fact that it is 
population-based with detailed information about the medications dispensed, and the infor-
mation including age and sex of patients. With these data, we were able to study the dispensa-
tion of the medications that are contraindicated in young individuals (chapter 3.1). For the 
identification of medication exposure, the Anatomical Therapeutic Chemical Classification (ATC) 
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of all medications were available [19]. Furthermore, we also had information on the dispensing 
date, the daily dosage and product name. Also, a relatively long history of this database was 
available (if born after 1990) which enabled us to study the medications dispensed since birth 
on the condition that they did not switch pharmacies. However, pharmacy record databases in 
itself are not suitable for investigating associations between medication exposure and health 
outcomes as the latter is unavailable. Also, there is no information about the indications for 
which the medications were prescribed. This collaborative pharmacy database is suitable for 
nationwide drug utilization studies for different types of medication. It may also give us an 
idea of any changes in prescription behavior compared to previous years as a relatively long 
history is available (since 1990) [18]. Furthermore, information about the type of prescriber 
and the postal code of the pharmacy are also available. This makes it possible to study the 
different prescription behaviors, also depending on the different regions. Another strength of 
this pharmacy database as opposed to prescription databases is that we have dispensing data 
instead of prescriptions as utilization data from GP databases, for instance, may overestimate 
actual drug use because not all prescriptions are filled at the pharmacy. However, one of the 
limitations is that it only covers the medication dispensed by community pharmacies and not 
the medications dispensed by hospital pharmacies, and no ‘over-the-counter’ drug use is reg-
istered. Also, we do not know if these medications are taken by patients. Therefore, it may not 
give us a complete overview of all medications that are used by patients.
In chapter 4.3 and 5.1, prescription data was used from the Integrated Primary Care In-
formation database. This is a longitudinal observational dynamic database containing medical 
records from more than 450 general practitioners (GP) in the Netherlands [20]. In contrast 
to the pharmacy record database, the GP database contains detailed information about the 
diagnosis and co-morbidities based on ICPC codes (International Classification of Primary Care). 
This enabled us to study the associations between medication exposure and certain health 
outcomes. Furthermore, a long follow-up period (since 1996) of patients was available, which 
makes it possible to study long-term effects of medications and the association with certain 
outcomes. Moreover, GP data  may give information about  the indication for therapy which is 
not available in pharmacy databases. However, patients may also switch between GP practices 
where the follow-up period will end once they leave a participating GP practice. This may result 
in a shorter follow-up period for an individual. As mentioned earlier, this database only contains 
prescription data. In the Netherlands, pharmacists also act as a gatekeeper and they may de-
cide that certain medications which are prescribed to them should not be given (e.g. because 
of a contraindication), of course only after discussing this first with the prescriber. Furthermore, 
lifestyle factors such as smoking or alcohol use may not always be captured in the database. 
Therefore, it will not be possible to adjust for these type of potential confounders.
The last database that was used in this thesis (chapter 4.1 and 4.2) is the database from the 
Generation R study. This study concerns a large prospective population-based cohort in which 
the health of children is investigated from fetal life onwards. Due to its prospective design, 
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detailed and extensive data have been collected, which includes questionnaires, interviews and 
behavioral observations. Also, information about their parents was collected such as certain 
lifestyle factors (smoking, alcohol use, caffeine intake), but also behavioral and demographic 
factors (ethnicity and education). Collecting information by conducting interviews is one way 
to gather important information in a consistent way. However, it was not be feasible to inter-
view all parents included in the study, because these interviews can be very time-consuming. 
Nevertheless, questionnaires were also used to collect information. The limitation of using 
questionnaires is that there is always a chance that not all parents will complete the question-
naire, which may results in missing values. In this case it is possible that either parts of the 
questionnaires were not completed or the entire questionnaire has not been completed. When 
this information is missing completely at random (missing status not related to either exposure 
or outcome), the data sample may still be unbiased and representative of the population. 
However, when the missing status is not completely at random, it can have a strong effect on 
the results and the conclusions drawn from these data. Furthermore, the use of questionnaires 
may also be prone to information bias as parents may be completing the questionnaires incor-
rectly (they do not remember or misunderstand the question). For the collection of information 
about the medications that were used by mothers during pregnancy or medications used by 
children we also used questionnaires but for the mothers we also had a printout of the medica-
tion records from the pharmacy to verify. Also, pharmacy records of all children until November 
2018 were collected recently which were linked to the other information that was obtained in 
the Generation R Study. This linkage enabled us to study the (long-term) effects of medications 
used by children and the association with health outcomes, of which both detailed information 
was available (such as the precise filling date, behavioral and demographic factors). In chapter 
2.1, we have shown that the use of medications reported by mothers (questionnaires) may be 
as important as medications found in the pharmacy records to have a complete overview of all 
medications that were used.
Difficulties in obtaining information on medication use
In chapter 4.1 and 4.2, we have used pharmacy record data to determine the initiation of, as 
well as the persistence and adherence to methylphenidate. Electronic pharmacy records of 
participants in the Generation R study were obtained from the Foundation for Pharmaceutical 
Statistics (SFK), where we faced some challenges. In order to receive pharmacy records from 
the SFK, unique identification numbers of the Generation R participants were needed. These 
numbers could only be found in the computer systems of the community pharmacies. We used 
the postal code of the child’s parents at study entry (between the years 2002 and 2006) and 
the postal code at the time of data collection (in 2017) to find the pharmacies of the children. 
All community pharmacies in the Rotterdam area (~80 pharmacies) were contacted and asked 
for consent to collect these identification numbers. The identification numbers of children were 
only collected when both parents gave consent. The recent change in the legislation where the 
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General Data Protection Regulation (GDPR) has replaced the Dutch Data Protection Act also 
affected the process of collecting pharmacy record data. This new European legislation has 
tightened the regulations and rules regarding the automatic processing of personal data. Due 
to this change, pharmacists were implementing measures to protect their data and limit the 
access, which was also one of the reasons that we were not able to collect pharmacy records of 
all children as some pharmacists were more reluctant to provide consent. Furthermore, there 
is the possibility that these children received their medication from other pharmacies. Until 
5 years ago, patients were designated to one pharmacy but nowadays patients are free to 
choose any pharmacy. Although no longer obligatory, most patients simply chose the pharmacy 
nearest to their home. Fortunately, however, many pharmacies are on collaborative computer 
networks and patients are recognized if they go to the adjacent pharmacy in the same neigh-
borhood. Finally, collecting the identification numbers of all Generation R participants is a time 
consuming process as these numbers all had to be found manually in the databases of the 
community pharmacies. Nevertheless, we were able to find the pharmacy record data of 5,068 
children, which was 74.4% of all children whose parents gave consent to retrieve the pharmacy 
record data.
PharMaColoGiCal TreaTMenT, is iT alwaYs The besT 
soluTion?
ADHD diagnosis in children and the influence of parents on the decision to 
initiate treatment and adherence
Behavioral and emotional problems have always been a challenge in terms of diagnosis and 
treatment as some people hide their symptoms and do not seek help. However, when we talk 
about children, the situation is much more complex. Children mostly rely on their parents as 
they can often not easily communicate their feelings, except for symptoms such as pain. The 
parents are usually the ones to notice any behavioral problems. These type of problems are, 
unlike other health outcomes (such as a high or low blood pressure), difficult to measure. It 
requires sufficient knowledge and experience to recognize behavioral problems, not only by 
general practitioners (GPs) but more importantly by parents, as they are the ones to visit the 
GP and experience the child’s behavior during the whole day. Attention deficit hyperactivity 
disorder (ADHD) is one of the examples where the diagnosis can be difficult, because of the 
different symptoms that characterize this disorder. Usually the externalizing symptoms, such 
as hyperactivity and impulsivity are seen as the core symptoms of ADHD which is also more 
common in boys than in girls [10]. This is encountered by many parents as ‘difficult behavior’ 
and one of the reasons that relatively more boys are receiving pharmacological treatment than 
girls [88]. Not only is the disorder less often recognized in girls than in boys, but the inter-
nalizing symptoms (which are more often seen in girls) are also less likely to be qualified for 
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pharmacological treatment as their symptoms are not considered to be severe enough [114]. 
Consequently, parents may find it more difficult to cope with the behavior of boys, which may 
also increase the likelihood of initiating treatment in  boys compared to girls. There are differ-
ent pharmacological treatment options available, such as dexamfetamine or atomoxetine, but 
methylphenidate is considered as the first-line treatment for ADHD. Methylphenidate is a psy-
chostimulant and acts by increasing the activity of dopamine and norepinephrine through inhi-
bition on reuptake of these neurotransmitters. Before considering pharmacological treatment, 
lifestyle advices are given (such as a structured daily programme). If not enough, behavioral 
therapy is preferred and only in some (severe) cases it may be necessary to try a combination 
with medicines [8]. Even when pharmacological therapy is proposed by the GP or specialist, the 
final decision to initiate it in children should be supported by their parents. Parents are in the 
end also responsible for making sure that their children are taking the medication according 
to the prescribed treatment regimen. However, parents are not always entirely involved in the 
decision-making process with the healthcare professionals [215]. For most parents it is difficult 
to find help and discuss alternative treatment options [216]. They feel the pressure from school 
or other family members or friends to make the right decision [116, 118]. This may also be 
one of the reasons that parents accept the pharmacological treatment for their child, even 
if they do not fully support this decision. Parents may accept pharmacological treatment for 
several reasons: 1) they fully rely on the doctor’s experience and knowledge as they want to do 
what helps most, 2) many children are using it nowadays so it is more or less socially accepted 
and considered worth trying [217]. These two reasons already show that parents are making 
decisions based on limited information. A previous study showed that some parents, in fact, 
prefer not to initiate medication because of the risks and because they do not like the idea of 
their child taking medication on a daily basis [146]. Therefore, it is important to understand and 
assess the attitude of parents towards initiating medication and consider their preferences in 
the decision-making process.
Parents will only be able to make the right decisions and follow the treatment schedule if 
they are fully aware of the risks and benefits of pharmacological treatment and understand the 
importance of adherence to treatment. Furthermore, information about the family character-
istics (such as the ethnicity, education level of parents, household income and whether or not 
they have to raise their child alone) should also be considered when deciding to initiate medica-
tion as these factors may also be an important factor in terms of child’s treatment adherence 
(chapter 4.2). After all, pharmacological treatment will not be effective if not taken according 
to the prescribed treatment regimen [218]. Therefore, the probability of non-adherence based 
on family characteristics should also be considered.
Undertreatment or overtreatment?
Earlier we discussed the differences between boys and girls in terms of initiating pharmaco-
logical treatment. This could mainly be explained by the differences in ADHD diagnosis which 
118 Chapter 6
General discussion
depend on the symptom profile of boys (ADHD) and girls (attention deficit disorder, ADD). The 
failure to recognize symptoms in girls may result in undertreatment of the condition. However, 
in chapter 4.2 we showed that even when there are no reported ADHD symptoms, boys were 
still more likely to receive methylphenidate treatment. Thus, girls receiving less treatment than 
boys could imply that girls with ADHD symptoms are undertreated. However, there is also a 
possibility that boys without ADHD are being overtreated [115] [172] [219]. Apart from the 
indications and symptoms presented by these children, the current knowledge about ADHD 
diagnosis and treatment may also influence prescribers. Also, the effectiveness of methylphe-
nidate in boys in terms of symptom improvement is easier to measure than in girls as the 
reduction of externalizing ADHD symptoms are more visible. [10, 113]. As our findings showed 
that medications were more often prescribed to boys irrespective of the presence of ADHD 
symptoms, it is suggested to conduct further research in a larger population. When conducting 
further research,  the absence of ADHD symptoms should be further investigated in children 
who have already started treatment with medication. Also, the combination with behavioral 
therapy should be considered.
There are also other factors that may determine whether or not a child will receive medica-
tion. The results of our study showed that children born to mothers with a non-western ethnic 
background are less likely to receive methylphenidate treatment than those born to native 
Dutch mothers. This could be explained by cultural factors, such as their view on problematic 
behavior in children or medical approaches and beliefs [220]. In some cultures, a child with 
symptoms of hyperactivity or impulsive behavior can be seen  as a child with high energy. Such 
parents may have a higher threshold for seeking help. Also, limited knowledge about ADHD or 
language barriers may be reasons that parents from certain cultures are less likely to visit their 
GP [220]. These challenges may lead to children with ADHD not receiving the treatment they 
need to alleviate their symptoms. Studies have shown that even when children with a non-
western background are formally diagnosed with ADHD, their parents do not always accept 
medication and prefer behavioral therapy over pharmacological therapy [125, 126]. Although 
this has been reported as undertreatment in ethnic minorities in most studies, we might have 
to ask ourselves whether there is not the potential of (over diagnosis and) overtreatment in the 
western population [219].
The recognition of ADHD has increased over the years along with the increase in use of 
medication to treat this disorder [182]. Treatment with medication has proven to be effec-
tive by relieving ADHD symptoms [84] even more rapidly than with behavioral therapy alone. 
However, medications do not permanently cure the disorder and when diagnosed in childhood 
it tends to persist in up to 65% of adolescents and adults [221], while the long-term effects of 
the medications on the brain are not known [222-224]. At some point, these children have to 
cope with these symptoms without using medication, which may also be extremely difficult. 
They may experience rebound effects, leading to another problem to deal with [225, 226]. 
Although undertreatment of ADHD may still be a problem, there are also concerns of unneces-
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sary medication use by children whose behavior may be managed through other means. It 
is important to focus on sufficiently informing parents on how to manage these behavioral 
problems by bringing more structure into their daily household. They should be informed, in 
the child’s early years about the behavioral problems that may occur in children, such as the 
age these problems usually occur or other factors that may trigger these problems. Parents can 
therefore take these factors into account when raising their child and adapt their parenting 
style. However, further research is needed to determine what factors (in early childhood) may 
prevent these behavior problems. Finally, it should also be considered that parents may also 
have behavioral or emotional problems themselves. They should receive a different type of 
support and information about how to raise children with behavioral problems.
Based on our results and the existing literature, we may conclude that it is important for 
parents to be aware of the child’s behavioral problems, but also to be informed as early as 
possible in order to timely recognize it. Pharmacological therapy may not always be necessary 
if parents are able to manage their child behaviorally (in early childhood) and avoid medication.
Contraindications
As previously discussed, not only the decision to start but also to discontinue treatment may be 
necessary as the long-term effects of medications are not always known. However, sometimes 
behavioral problems that were diagnosed during childhood may persist into adulthood. It 
is up to the specialist to determine whether continued treatment is necessary but then the 
risks should also be considered. Apart from the fact that the long-term effects on the brain 
are not known, methylphenidate was until recently also not approved for use in adults [21]. 
There were concerns about the cardiovascular risks when using methylphenidate, especially 
in the older population [4, 5]. Nevertheless, methylphenidate was still prescribed despite the 
potential risks, and this was allowed if prescribing followed the guidelines of the Dutch Society 
of Psychiatry [165]. Publications by the Foundation for Pharmaceutical Statistics (SFK) showed 
that the use of methylphenidate among the number of patients aged 6-15 years, has decreased 
since 2015. The other age groups showed an increase in the same period of time [6]. Although 
the increase in the older age groups has become less [7], a recently published study showed 
that ADHD among adults is increasing [227].
This is one of the examples where medications are prescribed despite the known potential 
long-term risks. However, in children age-related contraindications are common as many medi-
cations have not been tested in children for efficacy and safety. These medications are often 
prescribed off-label where the decision to prescribe medications is based on the need to treat 
and on experience and current knowledge about these medications. In some cases, healthcare 
professionals have to consult different information sources or the available literature about the 
use of certain medications in the different age groups. As prescribed earlier (chapter 3.1), the 
information sources provide inconsistent information about whether the medication can be 
used in a certain age group. In other cases, it is not clear why a medication is contraindicated 
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for a particular age group, which makes it difficult for a healthcare professional to make a deci-
sion to prescribe the medication. Furthermore, relative and absolute contraindications are also 
sometimes confused where ‘off-label’ is also branded as ‘contraindications’ in certain countries, 
such as in Korea where the lack of information on safety as well as efficacy is regarded as con-
traindications [228]. This can be misleading as off-label use can be implied as ‘being harmful’ 
where in fact the safety of the medication in certain age groups has not been established yet. 
Nevertheless, prescribing a contraindicated medication may sometimes be necessary and does 
not have to be considered bad practice. Therefore, further research is needed to assess the 
reason for prescribing particular medications despite their contraindication for age and if any of 
these contraindicated prescriptions has led to negative outcomes such as hospital admissions 
or serious adverse drug reactions. The Paediatric Regulation that came into force in the Euro-
pean Union in 2007, has already led to an improvement in the availability of information on the 
use of medicines for children [229]. Nevertheless, it remains a challenge to conduct the trials in 
children as there are some risks and pitfalls that need to be anticipated to ensure that children 
will benefit from this (such as a long approval process and complex ethical issues) [230].
When medications are used for other reasons than managing symptoms
Methylphenidate is considered safe when taken as prescribed and intended, but there is also 
a growing concern about potential misuse/abuse of prescription drugs [231].  A rise in methyl-
phenidate use in adults may also come with a high potential of abuse or misuse, for instance, 
by students, but also professionals or athletes as the use of these medications may increase 
the feeling of energy and productivity [232]. Furthermore, young people may also take this 
medication for recreational purposes [233]. The concern of abuse among this population is that 
they are not aware of the risks of using this medication and without any healthcare professional 
monitoring their use, it may become a serious problem. They may experience the negative 
adverse effects, such as anxiety or insomnia [234]. Furthermore, repeated abuse of this medi-
cation may become a learned behavior and as a consequence they may keep continuing using 
this medication despite a desire to quit, which may again lead to other problems.
Another medication which has also been increasingly discussed in terms of safety, are the 
antidepressants, in particular the serotonin reuptake inhibitors (SSRIs). The SSRIs are known to 
cause agitation and activation, especially at the start of treatment. This is also known from some 
older tricyclic antidepressants such as nortryptiline [212]. Patients who are still in a depressed 
mood in combination with these new symptoms, may be at an increased risk of suicide [235]. 
This has led to concerns when using this medication to treat depression. Suicidal thoughts 
and acts may already be present in patients with depression and the use of antidepressants 
may or may not be associated with this risk. Thus, looking for an association still remains a 
challenge. However, undiagnosed bipolar disorder may also be present in patients with depres-
sion, where the use of antidepressants may even worsen their mood. As a consequence it 
may lead to psychosis and an increased risk of suicide [16]. These are rare cases where the 
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use of antidepressants should be discontinued and appropriate treatment should be started. 
However, as many other disorders, these are difficult to measure and clinicians should be care-
ful when prescribing these medications. The currently available literature shows conflicting and 
inconclusive evidence [16] [205]. Despite of all this, care should still be taken to avoid harm 
in patients due to the use of particular medications, especially with these type of conditions.
fuTure researCh
The findings in this thesis show that more population-based research of drug effects is needed, 
especially in children and adolescents. Although clinical studies in children became more ac-
ceptable in the past years, there are still some challenges we may face such as the ethical con-
siderations. Also, limited data is available about the real-life effects of medications in children 
once the drug is marketed. Apart from the fact that more research is needed to study the safety 
and efficacy in children, this lack of knowledge regarding pediatric specific drug use is still an 
ongoing area which need to be studied further in post marketing studies.
In our study, we have investigated the prescription of methylphenidate in children with 
and without mother-reported ADHD symptoms, which showed differences between children 
with a western and non-western ethnic background but also between boys and girls. Further 
research in a larger population is needed to investigate the potential of overtreatment and un-
dertreatment in children with and without ADHD. When investigating this, it is also important 
to consider behavioral therapy, which may also vary across the different demographic groups 
as shown previously [125, 126].
Also, the potential of misuse or abuse could be addressed by studying the issue across 
different demographic groups (e.g. boys vs girls or western vs non-western). It could possibly 
give us more insight into the underlying reasons, which may hopefully lead to an improvement 
of the existing preventative measures.
Finally, we also discussed the age-related contraindicated medications which are sometimes 
still prescribed despite the contraindication. Therefore, the reasons for prescribing these age-
contraindicated medications should be further investigated, where we want to know whether 
these are prescribed because the risks were unknown or because of other reasons. In addition, 
this could be studied further, where we may investigate the association between the use of 
these age-related contraindicated medications and serious adverse drug reactions or hospital 
admissions as the outcome. Most studies on contraindicated medications are focusing on the 
teratogenic effects or drug interactions [236-238], but studies investigating the age-related 









This thesis comprises of studies where we used different information sources to answer ques-
tions related to the use of medication in children and adolescents.
Exposure to medication may already start at an early stage in the life cycle: the pregnancy 
period. Observational studies are often conducted to assess the risk of adverse perinatal out-
comes, as pregnant women are not included in clinical trials due to obvious ethical reasons. 
In these studies, different information sources can be used to determine medication exposure 
during pregnancy. Within the Generation R Study (chapter 2.1), we compared the self-reported 
medication use and the dispensed pharmacy records for different therapeutic classes of 
medication. In this chapter, we showed that selective serotonin reuptake inhibitors (SSRIs) and 
anti-asthmatics, which are medications used for chronic conditions, have a substantial or good 
concordance between self-reported medication and dispensed pharmacy records. Medications 
taken for acute conditions, such as the antibiotics, folic acid and antihistamines, had a lower 
concordance when comparing both information sources. Several factors, such as the ethnic 
background may have played a role in the self-reporting of medication use.
Apart from pregnant women, inclusion of children is also not very common, although more 
accepted than in the past. Medications prescribed to children are often not approved for use for 
this particular age group as the safety and effectiveness have not been studied yet. Sometimes 
the risks are known, but even then, these medications may still be prescribed or dispensed. In 
chapter 3.1, we determined the incidence and prevalence of age-related contraindicated medi-
cations that were dispensed to children. The findings of this chapter show that a substantial 
percentage of children received a medication which was contraindicated for that age group. 
The results also indicated that information about the contraindication is not always consistent 
between different sources and that information about the risks is often limited.
The question to consider pharmacological therapy to treat ADHD symptoms in children has 
been discussed extensively. The decision to start treatment with medication does not only lie 
with the specialist or prescriber, but also their parents as children often rely on them for sup-
port and management of these chronic conditions. In chapter 4.1, we investigated the maternal 
sociodemographic characteristics as determinants of methylphenidate initiation, which shows 
that maternal education is an important determinant of methylphenidate treatment. Also, the 
child’s sex and maternal ethnicity were found to be associated with initiating methylphenidate 
treatment, irrespective of the presence of clinically relevant ADHD symptoms.
Once children started treatment, several factors may influence adherence and persistence 
to treatment with methylphenidate. Chapter 4.2 shows that not only child’s but also family 
characteristics play an important role in treatment adherence. These results also show that 
children starting at an older age and girls were more likely to be non-persistent than younger 
children and boys. Considering these findings, it is important for prescribers to take these into 
account when initiating methylphenidate treatment.
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Drug treatment is often started during childhood, but it has also increasingly been pre-
scribed at an older age. Chapter 4.3 of this thesis, indicates that methylphenidate, which was 
started during childhood, was continued in half of the study population when reaching the age 
of 18 years. The majority of this group started treatment at adolescence which may explain the 
reason for continuing treatment at this age. Furthermore, we found that ~25% of our study 
population had a medication possession ratio above one, suggesting misuse or abuse of meth-
ylphenidate. These data suggest close monitoring of methylphenidate use and dispensation of 
these medications, in particular to patients aged 15 years and higher.
Furthermore, we investigated the association between antidepressant use and the risk of 
suicide of which the results are presented in chapter 5.1. The results of this study did not in-
dicate an increased risk of suicide after starting treatment with SSRIs, tricyclic antidepressants 
and other antidepressants when compared with past antidepressant use.









Dit proefschrift bestaat uit hoofdstukken, waarbij we gebruik hebben gemaakt van verschil-
lende informatiebronnen bij het beantwoorden van  vraagstukken die gerelateerd zijn aan het 
medicatiegebruik bij kinderen en adolescenten.
Medicatiegebruik begint al in de vroege fase van het leven, namelijk tijdens de zwanger-
schap. Observationele studies worden vaak uitgevoerd om het risico op ongunstige perinatale 
uitkomsten te beoordelen, omdat zwangere vrouwen, omwille van ethische redenen, niet kun-
nen deelnemen aan klinische studies. Bij deze studies kunnen verschillende informatiebronnen 
worden toegepast om het gebruik van medicatie tijdens de zwangerschap te bepalen. Binnen 
de Generation R studie (hoofdstuk 2.1) hebben we informatie over het medicatiegebruik, die 
verkregen is middels vragenlijsten en apotheekgegevens, vergeleken tussen verschillende 
therapeutische groepen. In dit hoofdstuk, tonen we aan dat de concordantie tussen het medi-
catiegebruik op basis van vragenlijsten en apotheekgegevens voor de chronisch gebruikte mid-
delen, zoals de selectieve serotonine heropnameremmers en de anti-astma middelen, vrij goed 
is. Medicijnen die gebruikt worden voor acute aandoeningen, zoals antibiotica, foliumzuur en 
allergiemiddelen, laten een lager concordantie zien wanneer we het medicatiegebruik op basis 
van beide informatiebronnen ook voor deze middelen vergelijken. Verschillende factoren, zoals 
etniciteit kunnen een rol hebben gespeeld bij het invullen van de vragenlijsten over het gebruik 
van medicatie tijdens de zwangerschap.
Naast zwangere vrouwen, komt het ook niet vaak voor dat kinderen aan klinische studies 
deelnemen, alhoewel dit tegenwoordig wel meer wordt geaccepteerd. Medicaties die worden 
voorgeschreven aan kinderen zijn vaak niet goedgekeurd voor het gebruik bij deze leeftijdsgroe-
pen, omdat de veiligheid en effectiviteit nog niet zijn vastgesteld. In sommige gevallen worden 
deze geneesmiddelen toch wel voorgeschreven of afgeleverd, ondanks de bekende risico’s 
bij het gebruik van deze middelen. In hoofdstuk 3.1 hebben we de incidentie en prevalentie 
berekend van de geneesmiddelen die bij verschillende leeftijdsgroepen gecontra-indiceerd 
zijn en toch aan de kinderen zijn afgeleverd. De bevindingen in dit hoofdstuk laten zien dat 
een aanzienlijk percentage kinderen een of meerdere geneesmiddelen hebben ontvangen die 
gecontra-indiceerd zijn voor de betreffende leeftijdsgroep. De resultaten geven ook aan dat de 
informatie over de contra-indicatie niet altijd consistent is tussen verschillende informatiebron-
nen. Tevens is de informatie over deze risico’s vrij beperkt.
De overweging om medicaties voor te schrijven bij de behandeling van ADHD (aandachtste-
kort-hyperkinetische stoornis) symptomen bij kinderen is een veelbesproken onderwerp. De 
beslissing om te starten met medicatie ligt niet alleen bij de specialist of voorschrijver, maar 
ook bij de ouders. Kinderen zijn namelijk vaak afhankelijk van hun ouders en vertrouwen op 
hun steun en begeleiding bij dit soort chronische aandoeningen. In hoofdstuk 4.1 hebben we 
de socio-demografische karakteristieken van de moeder als determinanten bestudeerd bij het 
starten van methylfenidaat bij kinderen. De bevindingen in dit hoofdstuk tonen aan dat de 
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opleiding van de moeder een belangrijke rol speelt bij het starten van methylfenidaat. Tevens 
laten deze resultaten zien dat het geslacht van het kind en de etniciteit van de moeder ook 
gerelateerd zijn aan het starten van methylfenidaat bij kinderen, ongeacht de aanwezigheid 
van ADHD symptomen.
Op het moment dat kinderen met methylfenidaat zijn gestart, kunnen verschillende facto-
ren van invloed zijn op de therapietrouw en de continuïteit van het gebruik van methylfenidaat 
(persistentie). Hoofdstuk 4.2 toont aan dat niet alleen de karakteristieken van het kind, maar 
ook van de familie een rol spelen bij therapietrouw. Deze resultaten laten ook zien dat meisjes 
en kinderen die op een later leeftijd zijn gestart, vaker stoppen dan jongens en kinderen die 
op een jonge leeftijd zijn gestart. Zodoende is het belangrijk dat voorschrijvers deze informatie 
meenemen bij de beslissing om met methylfenidaat te starten.
Methylfenidaat wordt vaak gestart op een jonge leeftijd (bij kinderen), maar het wordt 
ook in toenemende mate voorgeschreven aan ouderen. Hoofdstuk 4.3 van dit proefschrift 
geeft aan dat de helft van de studiepopulatie die op een jonge leeftijd met methylfenidaat is 
gestart, dit nog steeds gebruikt wanneer de leeftijd van 18 jaar is bereikt. De meerderheid van 
deze groep is op een late leeftijd gestart met methylfenidaat (15-17 jaar) en dat verklaart ook 
deels waarom deze patiënten het gebruik hiervan op de leeftijd van 18 jaar hebben voortgezet. 
Daarnaast geven de resultaten ook aan dat bij ongeveer 25% van de studiepopulatie meer 
geneesmiddelen bij de apotheek zijn afgeleverd dan zijn voorgeschreven (medication posses-
sion ratio boven 1.0). Dit suggereert dat methylfenidaat mogelijk voor andere redenen, dan 
voor de behandeling van ADHD symptomen, wordt gebruikt (misbruik). Gezien deze gegevens, 
is het belangrijk dat het gebruik en de aflevering van methylfenidaat goed in de gaten wordt 
gehouden, met name bij patiënten van 15 jaar en ouder.
Verder hebben wij ook de associatie tussen het gebruik van antidepressiva en het risico op 
suïcide bestudeerd, waarvan de resultaten zijn weergegeven in hoofdstuk 5.1. De resultaten 
van deze studie geven aan dat er geen verhoogd risico op suïcide is gevonden na het starten van 
de behandeling met antidepressiva. Hierbij hebben we de selectieve serotonine heropname 
remmers, tricyclische antidepressiva en de overige antidepressiva vergeleken met het gebruik 
van antidepressiva in het verleden.
Als laatst hebben we de resultaten in perspectief geplaatst in de discussie, waarbij ook een 
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